

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2002 ALABAMA

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE ND.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE D.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

- SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES
- SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65
- SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER
- SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74
- SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84
- SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLE

- APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES
- APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE D.2
 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a,b}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | No. of Benes | | | | | | No. of Bene Mos | | | | | |
|--|----------------|---------------|---------------|------------|----------|-------------------|------------------|----------------|----------------|--------------|-----------|-------------------|
| | All | Aged | Disabled | Adults | Children | Other/ Unknown | All | Aged | Disabled | Adults | Children | Other/ Unknown |
| All | 106,428 | 44,948 | 60,644 | 823 | 6 | 7 | 1,144,370 | 468,312 | 668,476 | 7,432 | 66 | 84 |
| Age | | | | | | | | | | | | |
| 5 and younger | 6 | 0 | 6 | 0 | 0 | 0 | 66 | 0 | 66 | 0 | 0 | 0 |
| 6-14 | 21 | 0 | 20 | 0 | 1 | 0 | 224 | 0 | 212 | 0 | 12 | 0 |
| 15-20 | 255 | 0 | 250 | 0 | 5 | 0 | 2,788 | 0 | 2,734 | 0 | 54 | 0 |
| 21-44 | 19,387 | 0 | 18,712 | 675 | 0 | 0 | 210,643 | 0 | 204,409 | 6,234 | 0 | 0 |
| 45-64 | 22,433 | 2 | 22,301 | 124 | 0 | 6 | 242,955 | 23 | 241,804 | 1,056 | 0 | 72 |
| 65-74 | 22,553 | 9,970 | 12,566 | 16 | 0 | 1 | 248,462 | 105,100 | 143,273 | 77 | 0 | 12 |
| 75-84 | 22,773 | 17,567 | 5,200 | 6 | 0 | 0 | 246,149 | 187,275 | 58,823 | 51 | 0 | 0 |
| 85 and older | 19,000 | 17,409 | 1,589 | 2 | 0 | 0 | 193,083 | 175,914 | 17,155 | 14 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 |
| Gender | | | | | | | | | | | | |
| Female | 73,739 | 35,884 | 37,108 | 736 | 4 | 7 | 798,018 | 377,562 | 413,555 | 6,770 | 47 | 84 |
| Male | 32,688 | 9,064 | 23,535 | 87 | 2 | 0 | 346,340 | 90,750 | 254,909 | 662 | 19 | 0 |
| Unknown | 1 | 0 | 1 | 0 | 0 | 0 | 12 | 0 | 12 | 0 | 0 | 0 |
| Race | | | | | | | | | | | | |
| White | 54,662 | 25,406 | 28,857 | 393 | 2 | 4 | 577,300 | 257,151 | 316,543 | 3,540 | 18 | 48 |
| African American | 41,822 | 15,420 | 25,978 | 418 | 3 | 3 | 459,505 | 166,536 | 289,109 | 3,788 | 36 | 36 |
| Other/unknown | 9,944 | 4,122 | 5,809 | 12 | 1 | 0 | 107,565 | 44,625 | 62,824 | 104 | 12 | 0 |
| Use of Nursing Facilities^c | | | | | | | | | | | | |
| Entire year | 17,137 | 14,231 | 2,906 | 0 | 0 | 0 | 170,983 | 139,358 | 31,625 | 0 | 0 | 0 |
| Part year | 6,886 | 5,500 | 1,386 | 0 | 0 | 0 | 67,252 | 52,867 | 14,385 | 0 | 0 | 0 |
| None | 82,405 | 25,217 | 56,352 | 823 | 6 | 7 | 906,135 | 276,087 | 622,466 | 7,432 | 66 | 84 |
| Maintenance Assistance Status | | | | | | | | | | | | |
| Cash | 75,152 | 23,371 | 51,492 | 288 | 1 | 0 | 837,390 | 261,073 | 573,902 | 2,403 | 12 | 0 |
| Medically needy | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 |
| Poverty-related | 2,759 | 1,185 | 1,434 | 133 | 0 | 7 | 25,148 | 11,430 | 12,665 | 969 | 0 | 84 |
| Other/unknown | 28,517 | 20,392 | 7,718 | 402 | 5 | 0 | 281,832 | 195,809 | 81,909 | 4,060 | 54 | 0 |
| Dual Medicare Status^d | | | | | | | | | | | | |
| Full dual, all year | 100,908 | 42,086 | 58,010 | 799 | 6 | 7 | 1,088,702 | 438,918 | 642,451 | 7,183 | 66 | 84 |
| Full dual, part year | 5,520 | 2,862 | 2,634 | 24 | 0 | 0 | 55,668 | 29,394 | 26,025 | 249 | 0 | 0 |
| Managed Care Status | | | | | | | | | | | | |
| FFS all year | 105,646 | 44,602 | 60,209 | 822 | 6 | 7 | 1,139,377 | 466,350 | 665,454 | 7,423 | 66 | 84 |
| FFS part year, with Rx claims | 700 | 309 | 390 | 1 | 0 | 0 | 4,500 | 1,743 | 2,748 | 9 | 0 | 0 |
| FFS part year, no Rx claims | 82 | 37 | 45 | 0 | 0 | 0 | 493 | 219 | 274 | 0 | 0 | 0 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table D.2 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- d. The "Full dual, all year" group contains beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefits during all months of Medicaid enrollment in 2002. The "Full dual, part year" group contains beneficiaries who had such benefits for some, but not all, months of their enrollment. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE D.3
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a,b}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | % with at Least One Rx | Mean No. of Rx | Mean Rx \$ | \$ per Rx | Mean \$, All Services | Rx \$ as % of All Services | No. of Benes |
|--|------------------------|----------------|------------|-----------|-----------------------|----------------------------|--------------|
| All | 89.0 % | 45.5 | \$2,024 | \$45 | \$12,411 | 16.3 % | 106,428 |
| Age | | | | | | | |
| 5 and younger | 100.0 | 61.3 | 7,171 | 117 | 37,595 | 19.1 | 6 |
| 6-14 | 90.5 | 41.2 | 7,609 | 185 | 28,423 | 26.8 | 21 |
| 15-20 | 75.3 | 17.6 | 1,561 | 89 | 6,876 | 22.7 | 255 |
| 21-44 | 79.9 | 28.3 | 1,738 | 62 | 7,133 | 24.4 | 19,387 |
| 45-64 | 88.3 | 48.9 | 2,355 | 48 | 10,476 | 22.5 | 22,433 |
| 65-74 | 89.0 | 48.6 | 2,008 | 41 | 10,035 | 20.0 | 22,553 |
| 75-84 | 92.8 | 51.4 | 2,063 | 40 | 14,643 | 14.1 | 22,773 |
| 85 and older | 94.8 | 48.9 | 1,897 | 39 | 20,275 | 9.4 | 19,000 |
| Unknown | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0 |
| Basis of Eligibility^c | | | | | | | |
| Aged | 91.1 | 47.2 | 1,901 | 40 | 16,188 | 11.7 | 44,948 |
| Disabled | 88.1 | 44.7 | 2,134 | 48 | 9,754 | 21.9 | 60,644 |
| Adults | 47.8 | 14.3 | 670 | 47 | 1,907 | 35.1 | 823 |
| Children | 66.7 | 25.5 | 2,117 | 83 | 7,439 | 28.5 | 6 |
| Unknown | 100.0 | 42.3 | 1,868 | 44 | 17,933 | 10.4 | 7 |
| Gender | | | | | | | |
| Female | 92.0 | 50.4 | 2,146 | 43 | 12,946 | 16.6 | 73,739 |
| Male | 82.2 | 34.5 | 1,749 | 51 | 11,204 | 15.6 | 32,688 |
| Unknown | 100.0 | 10.0 | 423 | 42 | 2,087 | 20.3 | 1 |
| Race | | | | | | | |
| White | 90.2 | 52.3 | 2,356 | 45 | 15,452 | 15.2 | 54,662 |
| African American | 87.5 | 37.1 | 1,627 | 44 | 9,936 | 16.4 | 41,822 |
| Other/unknown | 88.8 | 43.5 | 1,869 | 43 | 6,105 | 30.6 | 9,944 |
| Use of Nursing Facilities^d | | | | | | | |
| Entire year | 97.3 | 64.8 | 2,844 | 44 | 34,873 | 8.2 | 17,137 |
| Part year | 94.9 | 48.9 | 2,184 | 45 | 23,778 | 9.2 | 6,886 |
| None | 86.8 | 41.2 | 1,840 | 45 | 6,790 | 27.1 | 82,405 |
| Maintenance Assistance Status | | | | | | | |
| Cash | 89.4 | 43.2 | 1,906 | 44 | 6,784 | 28.1 | 75,152 |
| Medically needy | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0 |
| Poverty related | 49.6 | 12.3 | 497 | 40 | 3,565 | 13.9 | 2,759 |
| Other/unknown | 91.9 | 54.8 | 2,484 | 45 | 28,094 | 8.8 | 28,517 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table D.3 includes beneficiaries represented by Cell G of Table 1.
 - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
 - d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.4
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | Mean No. of Rx | Mean Rx \$ | Rx \$ as % of All Services | No. of Rx, % with: | | | | | | Mean \$, All Services | Benes | Bene Mos |
|--|----------------|--------------|----------------------------|--------------------|----------------------------|----------------------------|----------------------------|-----------------------------|--------------|-----------------------|----------------|------------------|
| | | | | None | More than 0, but 1 or Less | More than 1, but 2 or Less | More than 2, but 5 or Less | More than 5, but 10 or Less | More than 10 | | | |
| All | 4.2 | \$188 | 16.3 % | 11.0 % | 16.5 % | 11.2 % | 30.7 % | 24.5 % | 6.0 % | \$1,154 | 106,428 | 1,144,370 |
| Age | | | | | | | | | | | | |
| 5 and younger | 5.6 | 652 | 19.1 | 0.0 | 0.0 | 0.0 | 66.7 | 33.3 | 0.0 | 3,418 | 6 | 66 |
| 6-14 | 3.9 | 713 | 26.8 | 9.5 | 23.8 | 0.0 | 38.1 | 28.6 | 0.0 | 2,665 | 21 | 224 |
| 15-20 | 1.6 | 143 | 22.7 | 24.7 | 39.6 | 11.0 | 16.5 | 8.2 | 0.0 | 629 | 255 | 2,788 |
| 21-44 | 2.6 | 160 | 24.4 | 20.1 | 29.8 | 12.9 | 22.8 | 11.7 | 2.7 | 657 | 19,387 | 210,643 |
| 45-64 | 4.5 | 217 | 22.5 | 11.7 | 15.7 | 10.7 | 29.7 | 24.9 | 7.4 | 967 | 22,433 | 242,955 |
| 65-74 | 4.4 | 182 | 20.0 | 11.0 | 14.8 | 10.8 | 31.0 | 25.7 | 6.6 | 911 | 22,553 | 248,462 |
| 75-84 | 4.8 | 191 | 14.1 | 7.2 | 11.9 | 10.8 | 34.0 | 28.9 | 7.2 | 1,355 | 22,773 | 246,149 |
| 85 and older | 4.8 | 187 | 9.4 | 5.2 | 11.1 | 11.2 | 36.0 | 30.7 | 5.9 | 1,995 | 19,000 | 193,083 |
| Unknown | 0.0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 |
| Basis of Eligibility^c | | | | | | | | | | | | |
| Aged | 4.5 | 182 | 11.7 | 8.9 | 12.9 | 11.1 | 33.4 | 27.4 | 6.3 | 1,554 | 44,948 | 468,312 |
| Disabled | 4.1 | 194 | 21.9 | 11.9 | 19.2 | 11.4 | 28.9 | 22.6 | 5.9 | 885 | 60,644 | 668,476 |
| Adults | 1.6 | 74 | 35.1 | 52.2 | 15.9 | 7.3 | 14.7 | 8.1 | 1.7 | 211 | 823 | 7,432 |
| Children | 2.3 | 193 | 28.5 | 33.3 | 16.7 | 33.3 | 0.0 | 16.7 | 0.0 | 676 | 6 | 66 |
| Unknown | 3.5 | 156 | 10.4 | 0.0 | 0.0 | 42.9 | 42.9 | 14.3 | 0.0 | 1,495 | 7 | 84 |
| Gender | | | | | | | | | | | | |
| Female | 4.7 | 198 | 16.6 | 8.0 | 13.8 | 11.1 | 32.6 | 27.6 | 7.1 | 1,196 | 73,739 | 798,018 |
| Male | 3.3 | 165 | 15.6 | 17.8 | 22.7 | 11.6 | 26.6 | 17.5 | 3.8 | 1,057 | 32,688 | 346,340 |
| Unknown | 0.8 | 35 | 20.3 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 174 | 1 | 12 |
| Race | | | | | | | | | | | | |
| White | 5.0 | 223 | 15.2 | 9.8 | 12.7 | 9.4 | 29.8 | 29.5 | 8.8 | 1,463 | 54,662 | 577,300 |
| African American | 3.4 | 148 | 16.4 | 12.5 | 21.2 | 13.4 | 31.6 | 18.5 | 2.7 | 904 | 41,822 | 459,505 |
| Other/unknown | 4.0 | 173 | 30.6 | 11.2 | 17.8 | 12.0 | 32.2 | 21.9 | 4.9 | 564 | 9,944 | 107,565 |
| use of nursing Facilities^d | | | | | | | | | | | | |
| Entire year | 6.5 | 285 | 8.2 | 2.7 | 4.9 | 6.8 | 31.1 | 40.6 | 13.8 | 3,495 | 17,137 | 170,983 |
| Part year | 5.0 | 224 | 9.2 | 5.1 | 11.4 | 10.4 | 35.4 | 30.8 | 6.9 | 2,435 | 6,886 | 67,252 |
| None | 3.8 | 167 | 27.1 | 13.2 | 19.4 | 12.2 | 30.2 | 20.6 | 4.4 | 618 | 82,405 | 906,135 |
| Maintenance Assistance Status | | | | | | | | | | | | |
| Cash | 3.9 | 171 | 28.1 | 10.6 | 19.2 | 12.4 | 31.4 | 21.8 | 4.6 | 609 | 75,152 | 837,390 |
| Medically needy | 0.0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 |
| Poverty related | 1.4 | 55 | 13.9 | 50.4 | 22.8 | 9.2 | 12.3 | 4.5 | 0.9 | 391 | 2,759 | 25,148 |
| Other/unknown | 5.5 | 251 | 8.8 | 8.1 | 8.7 | 8.5 | 30.8 | 33.5 | 10.4 | 2,843 | 28,517 | 281,832 |

Table D4

Dual Eligible Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table D.4 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table D.5 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alabama, 0.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Therapeutic Category | No. of Rx per Bene Mo among Users | | | \$ per Bene Mo among Users | | | \$ per Rx | | | Users | | | | | | | |
|---|-----------------------------------|---------------------|-----------------------|----------------------------|---------------------|-----------------------|-----------|---------------------|-----------------------|-------|-------------------|---------------|-----------------|--------------|---------|---------|---------|
| | Total | Patented Brand-Name | Off-Patent Brand-Name | Total | Patented Brand-Name | Off-Patent Brand-Name | Total | Patented Brand-Name | Off-Patent Brand-Name | Total | No. of Dual Benes | As % of Benes | No. of Bene Mos | | | | |
| | | | | | | | | | | | | | | Generic | Generic | Generic | Generic |
| Anti-infective Agents | 0.3 | 0.2 | 0.0 | 0.2 | \$19 | \$15 | \$1 | \$2 | \$57 | \$94 | \$78 | \$14 | 227,847 | \$12,971,891 | 62,190 | 58.4 % | 695,668 |
| Biologics | 0.1 | 0.1 | 0.0 | 0.0 | 5 | 1 | 2 | 2 | 52 | 13 | 3,356 | 112 | 3,496 | 182,843 | 3,131 | 2.9 | 35,696 |
| Antineoplastic Agents | 0.5 | 0.1 | 0.1 | 0.3 | 74 | 34 | 13 | 27 | 156 | 249 | 210 | 98 | 27,795 | 4,339,951 | 5,705 | 5.4 | 58,799 |
| Endocrine/Metabolic Drugs | 0.9 | 0.5 | 0.1 | 0.3 | 37 | 29 | 2 | 5 | 40 | 58 | 27 | 16 | 477,163 | 19,049,141 | 46,109 | 43.3 | 513,370 |
| Cardiovascular Agents | 1.7 | 0.6 | 0.1 | 1.0 | 56 | 36 | 4 | 16 | 32 | 58 | 30 | 17 | 1,330,712 | 42,925,285 | 69,216 | 65.0 | 764,163 |
| Respiratory Agents | 0.6 | 0.2 | 0.1 | 0.3 | 21 | 14 | 2 | 5 | 36 | 64 | 26 | 18 | 311,918 | 11,373,784 | 47,695 | 44.8 | 535,384 |
| Gastrointestinal Agents | 0.7 | 0.1 | 0.0 | 0.5 | 25 | 14 | 1 | 11 | 39 | 111 | 79 | 20 | 316,524 | 12,230,820 | 43,544 | 40.9 | 485,190 |
| Genitourinary Agents | 0.4 | 0.3 | 0.0 | 0.1 | 23 | 21 | 0 | 2 | 55 | 67 | 30 | 17 | 75,683 | 4,182,136 | 16,298 | 15.3 | 183,056 |
| CNS Drugs | 1.1 | 0.6 | 0.0 | 0.5 | 78 | 63 | 3 | 12 | 70 | 113 | 76 | 23 | 655,389 | 46,082,458 | 53,557 | 50.3 | 588,618 |
| Stimulants/Anti-obesity/Anorexia | 0.5 | 0.2 | 0.1 | 0.2 | 37 | 25 | 5 | 7 | 80 | 131 | 77 | 35 | 4,051 | 324,211 | 794 | 0.7 | 8,847 |
| Miscellaneous Psychological/Neurological Agents | 0.7 | 0.6 | 0.0 | 0.1 | 77 | 76 | 0 | 1 | 117 | 127 | 10 | 23 | 51,016 | 5,964,510 | 7,217 | 6.8 | 76,965 |
| Analgesics and Anesthetics | 0.7 | 0.1 | 0.0 | 0.6 | 26 | 15 | 2 | 9 | 36 | 127 | 51 | 15 | 476,878 | 17,267,882 | 58,824 | 55.3 | 656,268 |
| Neuromuscular Agents | 0.8 | 0.3 | 0.1 | 0.4 | 42 | 29 | 4 | 9 | 52 | 97 | 48 | 21 | 299,386 | 15,646,075 | 33,304 | 31.3 | 372,280 |
| Nutritional Products | 0.7 | 0.0 | 0.1 | 0.6 | 11 | 1 | 1 | 9 | 16 | 41 | 23 | 15 | 207,909 | 3,402,051 | 28,932 | 27.2 | 315,956 |
| Hematological Agents | 0.7 | 0.3 | 0.1 | 0.3 | 40 | 33 | 2 | 5 | 57 | 127 | 20 | 17 | 175,245 | 10,072,963 | 22,862 | 21.5 | 250,121 |
| Topical Products | 0.4 | 0.2 | 0.0 | 0.2 | 15 | 11 | 1 | 3 | 38 | 54 | 42 | 19 | 186,599 | 7,099,311 | 41,362 | 38.9 | 466,105 |
| Miscellaneous Products | 0.5 | 0.2 | 0.1 | 0.2 | 92 | 60 | 19 | 13 | 198 | 375 | 278 | 56 | 10,775 | 2,137,127 | 2,181 | 2.0 | 23,297 |
| Unknown Therapeutic Category | 0.2 | 0.0 | 0.0 | 0.0 | 5 | 0 | 0 | 0 | 20 | 0 | 0 | 0 | 7,510 | 153,392 | 3,002 | 2.8 | 33,210 |
| TOTAL NO. OF RX AND RX \$ | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 4,845,896 | 215,405,831 | n.a. | n.a. | n.a. |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table D.6 includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2002. A beneficiary who used drugs from two or more categories was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mdmb.asp (May 13 2003).
- d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alabama, 0.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mdmb.asp (May 13 2003).
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.7
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Top 10 Drug Groups | Users | | | | Among Users | | |
|-----------------------|----------------------|---------|--------------------|-----------------|-----------------------|-----------|-------------------|
| | Total Medicaid Rx \$ | No. | As % of Dual Benes | No. of Bene Mos | No. of Rx per Bene Mo | \$ per Rx | Rx \$ per Bene Mo |
| ANTIPSYCHOTICS | \$25,040,155 | 23,502 | 22.1 % | 260,075 | 0.6 | \$151 | \$96 |
| ANTIDEPRESSANTS | 16,863,922 | 46,822 | 44.0 | 519,597 | 0.6 | 55 | 32 |
| ANTI-DIABETIC | 14,093,452 | 35,182 | 33.1 | 395,272 | 0.7 | 52 | 36 |
| ANTI-HYPERTENSIVE | 12,890,476 | 51,931 | 48.8 | 584,546 | 0.6 | 34 | 22 |
| ANTI-CONVULSANT | 12,420,033 | 25,238 | 23.7 | 282,675 | 0.7 | 65 | 44 |
| ANTI-HYPERLIPIDEMIC | 10,964,841 | 19,228 | 18.1 | 220,473 | 0.6 | 80 | 50 |
| ANALGESICS - Narcotic | 10,682,867 | 72,915 | 68.5 | 823,100 | 0.4 | 35 | 13 |
| CALCIUM BLOCKERS | 8,962,981 | 23,889 | 22.4 | 268,410 | 0.7 | 46 | 33 |
| ULCER DRUGS | 8,792,606 | 41,292 | 38.8 | 465,304 | 0.5 | 40 | 19 |
| ANTI-ASTHMATIC | 7,255,997 | 33,026 | 31.0 | 367,008 | 0.4 | 49 | 20 |
| Total | 127,967,330 | 373,025 | | 4,186,460 | n.a. | n.a. | n.a. |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table D.7 includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement; n.a. = not applicable.

TABLE D.7A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | All Top 10 Drug Groups | | | | | ANTIPSYCHOTICS | | | | | ANTIDEPRESSANTS | | | | | | |
|-----------------------------|------------------------|----------------------|---------------|--------------------------|-----------------------------|----------------|-------------|---------------|--------------------------|-----------------------------|-----------------|-------------|---------------|--------------------------|-----------------------------|----------------|-------------|
| | No. of Rx | Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ |
| All | 2,308,590 | \$127,967,330 | 23,502 | 22.1 % | 260,075 | 0.6 | \$96 | 46,822 | 44.0 % | 519,597 | 0.6 | \$33 | 46,822 | 44.0 % | 519,597 | 0.6 | \$33 |
| Female | 1,723,455 | 91,660,767 | 15,320 | 20.8 | 168,967 | 0.6 | 86 | 36,174 | 49.1 | 402,704 | 0.6 | 33 | 36,174 | 49.1 | 402,704 | 0.6 | 33 |
| Disabled | 957,059 | 53,992,498 | 8,189 | 22.1 | 93,881 | 0.6 | 95 | 20,922 | 56.4 | 238,880 | 0.6 | 31 | 20,922 | 56.4 | 238,880 | 0.6 | 31 |
| 5 and younger | 8 | 712 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 65 | 4,229 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 823 | 57,875 | 14 | 12.3 | 148 | 0.5 | 79 | 27 | 23.7 | 284 | 0.4 | 29 | 27 | 23.7 | 284 | 0.4 | 29 |
| 21-44 | 152,048 | 10,292,552 | 2,534 | 28.3 | 29,054 | 0.6 | 96 | 5,316 | 59.3 | 60,570 | 0.5 | 29 | 5,316 | 59.3 | 60,570 | 0.5 | 29 |
| 45-64 | 396,847 | 23,308,151 | 3,222 | 23.3 | 36,993 | 0.6 | 103 | 9,581 | 69.4 | 109,060 | 0.6 | 32 | 9,581 | 69.4 | 109,060 | 0.6 | 32 |
| 65-74 | 271,524 | 13,941,024 | 1,417 | 16.2 | 16,424 | 0.6 | 92 | 4,044 | 46.3 | 46,808 | 0.6 | 29 | 4,044 | 46.3 | 46,808 | 0.6 | 29 |
| 75-84 | 107,993 | 5,139,066 | 769 | 18.6 | 8,742 | 0.6 | 71 | 1,502 | 36.4 | 17,148 | 0.6 | 31 | 1,502 | 36.4 | 17,148 | 0.6 | 31 |
| 85 and older | 27,751 | 1,248,889 | 233 | 17.3 | 2,520 | 0.5 | 62 | 452 | 33.5 | 5,010 | 0.6 | 32 | 452 | 33.5 | 5,010 | 0.6 | 32 |
| Other Eligibles | 766,396 | 37,668,269 | 7,131 | 19.5 | 75,086 | 0.6 | 76 | 15,252 | 41.6 | 163,824 | 0.6 | 35 | 15,252 | 41.6 | 163,824 | 0.6 | 35 |
| 5 and younger | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 10 | 403 | 1 | 25.0 | 12 | 0.1 | 12 | 2 | 50.0 | 24 | 0.1 | 6 | 2 | 50.0 | 24 | 0.1 | 6 |
| 21-44 | 2,523 | 163,082 | 45 | 7.2 | 488 | 0.3 | 65 | 137 | 22.0 | 1,345 | 0.4 | 24 | 137 | 22.0 | 1,345 | 0.4 | 24 |
| 45-64 | 1,619 | 86,799 | 16 | 15.8 | 181 | 0.5 | 65 | 66 | 65.3 | 606 | 0.4 | 23 | 66 | 65.3 | 606 | 0.4 | 23 |
| 65-74 | 139,930 | 7,300,104 | 897 | 13.1 | 9,704 | 0.6 | 94 | 2,372 | 34.6 | 26,127 | 0.6 | 31 | 2,372 | 34.6 | 26,127 | 0.6 | 31 |
| 75-84 | 334,074 | 16,520,062 | 2,773 | 19.7 | 29,582 | 0.6 | 78 | 6,134 | 43.6 | 66,881 | 0.6 | 35 | 6,134 | 43.6 | 66,881 | 0.6 | 35 |
| 85 and older | 288,240 | 13,597,819 | 3,399 | 22.7 | 35,119 | 0.6 | 69 | 6,541 | 43.7 | 68,841 | 0.7 | 38 | 6,541 | 43.7 | 68,841 | 0.7 | 38 |
| Male | 585,128 | 36,306,268 | 8,182 | 25.0 | 91,108 | 0.7 | 115 | 10,646 | 32.6 | 116,869 | 0.6 | 32 | 10,646 | 32.6 | 116,869 | 0.6 | 32 |
| Disabled | 424,704 | 28,334,463 | 6,350 | 27.0 | 72,596 | 0.7 | 125 | 7,603 | 32.3 | 85,834 | 0.6 | 31 | 7,603 | 32.3 | 85,834 | 0.6 | 31 |
| 5 and younger | 67 | 3,634 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 76 | 5,142 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 1,174 | 103,118 | 28 | 20.6 | 326 | 0.8 | 169 | 26 | 19.1 | 295 | 0.5 | 33 | 26 | 19.1 | 295 | 0.5 | 33 |
| 21-44 | 131,499 | 11,086,826 | 3,276 | 33.6 | 37,556 | 0.7 | 130 | 3,242 | 33.3 | 36,659 | 0.5 | 31 | 3,242 | 33.3 | 36,659 | 0.5 | 31 |
| 45-64 | 175,895 | 11,290,333 | 2,238 | 26.4 | 25,540 | 0.8 | 128 | 2,935 | 34.6 | 32,890 | 0.6 | 31 | 2,935 | 34.6 | 32,890 | 0.6 | 31 |
| 65-74 | 89,740 | 4,607,274 | 567 | 14.8 | 6,455 | 0.7 | 94 | 1,064 | 27.7 | 12,143 | 0.6 | 29 | 1,064 | 27.7 | 12,143 | 0.6 | 29 |
| 75-84 | 22,363 | 1,066,135 | 200 | 18.7 | 2,297 | 0.7 | 87 | 285 | 26.6 | 3,273 | 0.6 | 29 | 285 | 26.6 | 3,273 | 0.6 | 29 |
| 85 and older | 3,890 | 172,001 | 41 | 17.2 | 422 | 0.7 | 88 | 51 | 21.3 | 574 | 0.7 | 34 | 51 | 21.3 | 574 | 0.7 | 34 |
| Other Eligibles | 160,424 | 7,971,805 | 1,832 | 20.0 | 18,512 | 0.6 | 76 | 3,043 | 33.2 | 31,035 | 0.6 | 36 | 3,043 | 33.2 | 31,035 | 0.6 | 36 |
| 5 and younger | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 24 | 1,019 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 5 | 753 | 1 | 100.0 | 7 | 0.7 | 108 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 21-44 | 710 | 50,661 | 4 | 7.5 | 30 | 0.3 | 23 | 36 | 67.9 | 299 | 0.4 | 25 | 36 | 67.9 | 299 | 0.4 | 25 |
| 45-64 | 459 | 22,466 | 4 | 12.9 | 38 | 0.7 | 59 | 13 | 41.9 | 89 | 0.7 | 37 | 13 | 41.9 | 89 | 0.7 | 37 |
| 65-74 | 50,632 | 2,532,102 | 449 | 14.3 | 4,846 | 0.6 | 80 | 816 | 26.1 | 8,693 | 0.6 | 33 | 816 | 26.1 | 8,693 | 0.6 | 33 |
| 75-84 | 67,890 | 3,414,779 | 796 | 22.8 | 8,095 | 0.6 | 81 | 1,258 | 36.1 | 12,973 | 0.7 | 36 | 1,258 | 36.1 | 12,973 | 0.7 | 36 |
| 85 and older | 40,704 | 1,950,025 | 578 | 23.6 | 5,496 | 0.6 | 66 | 920 | 37.6 | 8,981 | 0.7 | 39 | 920 | 37.6 | 8,981 | 0.7 | 39 |
| Unknown | 7 | 295 | 0 | 0.0 | 0 | 0.0 | 0 | 2 | 200.0 | 24 | 0.1 | 10 | 2 | 200.0 | 24 | 0.1 | 10 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table D.7A includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mdmb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.7B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | ANTIDIABETIC | | | | | ANTIHYPERTENSIVE | | | | | ANTICONVULSANT | | | | |
|-----------------------------|---------------|--------------------------|-----------------------------|------------|-------------|------------------|--------------------------|-----------------------------|------------|-------------|----------------|--------------------------|-----------------------------|------------|-------------|
| | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean Rx | Mean Rx \$ |
| All | 35,182 | 33.1 % | 395,272 | 0.7 | \$36 | 51,931 | 48.8 % | 584,546 | 0.6 | \$22 | 25,238 | 23.7 % | 282,675 | 0.7 | \$44 |
| Female | 27,738 | 37.6 | 312,644 | 0.7 | 36 | 39,152 | 53.1 | 442,182 | 0.6 | 23 | 17,096 | 23.2 | 191,615 | 0.6 | 41 |
| Disabled | 15,370 | 41.4 | 177,046 | 0.7 | 38 | 19,761 | 53.3 | 227,529 | 0.6 | 22 | 10,994 | 29.6 | 125,870 | 0.6 | 45 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 3 | 27.3 | 36 | 0.1 | 3 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 6 | 5.3 | 72 | 0.6 | 50 | 11 | 9.6 | 132 | 0.6 | 18 | 20 | 17.5 | 215 | 0.7 | 75 |
| 21-44 | 1,573 | 17.5 | 17,957 | 0.6 | 35 | 1,966 | 21.9 | 22,385 | 0.5 | 17 | 3,296 | 36.8 | 37,580 | 0.6 | 55 |
| 45-64 | 6,253 | 45.3 | 71,747 | 0.6 | 39 | 7,738 | 56.0 | 88,331 | 0.6 | 21 | 4,777 | 34.6 | 54,590 | 0.6 | 45 |
| 65-74 | 5,177 | 59.3 | 60,344 | 0.7 | 39 | 6,458 | 74.0 | 75,432 | 0.7 | 24 | 2,012 | 23.1 | 23,341 | 0.6 | 35 |
| 75-84 | 1,912 | 46.3 | 21,986 | 0.7 | 34 | 2,833 | 68.6 | 32,817 | 0.7 | 24 | 716 | 17.3 | 8,254 | 0.6 | 31 |
| 85 and older | 449 | 33.3 | 4,940 | 0.7 | 29 | 752 | 55.7 | 8,396 | 0.7 | 24 | 173 | 12.8 | 1,890 | 0.7 | 30 |
| Other Eligibles | 12,368 | 33.8 | 135,598 | 0.7 | 33 | 19,391 | 52.9 | 214,653 | 0.7 | 23 | 6,102 | 16.7 | 65,745 | 0.7 | 32 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 25.0 | 12 | 0.1 | 5 |
| 21-44 | 33 | 5.3 | 251 | 0.6 | 36 | 45 | 7.2 | 371 | 0.4 | 13 | 67 | 10.8 | 627 | 0.4 | 40 |
| 45-64 | 30 | 29.7 | 262 | 0.7 | 44 | 53 | 52.5 | 510 | 0.5 | 17 | 21 | 20.8 | 230 | 0.4 | 21 |
| 65-74 | 2,780 | 40.5 | 30,858 | 0.7 | 36 | 3,989 | 58.2 | 44,820 | 0.6 | 23 | 1,129 | 16.5 | 12,340 | 0.6 | 37 |
| 75-84 | 5,661 | 40.2 | 63,217 | 0.7 | 34 | 8,477 | 60.2 | 95,525 | 0.7 | 23 | 2,642 | 18.8 | 28,879 | 0.7 | 33 |
| 85 and older | 3,864 | 25.8 | 41,010 | 0.7 | 29 | 6,827 | 45.6 | 73,427 | 0.7 | 23 | 2,242 | 15.0 | 23,657 | 0.7 | 30 |
| Male | 7,444 | 22.8 | 82,628 | 0.7 | 36 | 12,779 | 39.1 | 142,364 | 0.6 | 21 | 8,141 | 24.9 | 91,048 | 0.7 | 51 |
| Disabled | 5,015 | 21.3 | 56,775 | 0.7 | 38 | 8,464 | 36.0 | 95,769 | 0.6 | 21 | 6,523 | 27.7 | 74,286 | 0.7 | 54 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 3 | 33.3 | 29 | 0.3 | 9 | 1 | 11.1 | 12 | 0.9 | 19 |
| 15-20 | 4 | 2.9 | 48 | 0.6 | 22 | 19 | 14.0 | 195 | 0.7 | 27 | 22 | 16.2 | 245 | 0.8 | 56 |
| 21-44 | 1,000 | 10.3 | 11,370 | 0.6 | 37 | 1,850 | 19.0 | 20,939 | 0.5 | 19 | 2,974 | 30.5 | 33,989 | 0.7 | 62 |
| 45-64 | 2,393 | 28.2 | 26,838 | 0.6 | 38 | 3,686 | 43.4 | 41,186 | 0.6 | 20 | 2,562 | 30.2 | 29,114 | 0.8 | 53 |
| 65-74 | 1,268 | 33.0 | 14,689 | 0.7 | 39 | 2,220 | 57.8 | 25,579 | 0.7 | 22 | 724 | 18.9 | 8,253 | 0.7 | 38 |
| 75-84 | 320 | 29.9 | 3,553 | 0.7 | 34 | 585 | 54.6 | 6,682 | 0.6 | 21 | 196 | 18.3 | 2,208 | 0.7 | 30 |
| 85 and older | 30 | 12.6 | 277 | 0.7 | 23 | 101 | 42.3 | 1,159 | 0.7 | 21 | 44 | 18.4 | 465 | 0.7 | 31 |
| Other Eligibles | 2,429 | 26.5 | 25,853 | 0.7 | 33 | 4,315 | 47.1 | 46,595 | 0.6 | 21 | 1,618 | 17.7 | 16,762 | 0.7 | 34 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 100.0 | 12 | 1.0 | 33 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 21-44 | 4 | 7.5 | 29 | 0.8 | 43 | 17 | 32.1 | 113 | 0.5 | 16 | 16 | 30.2 | 125 | 0.8 | 101 |
| 45-64 | 12 | 38.7 | 112 | 0.5 | 22 | 9 | 29.0 | 83 | 0.7 | 23 | 5 | 16.1 | 54 | 0.8 | 68 |
| 65-74 | 830 | 26.5 | 9,029 | 0.7 | 33 | 1,492 | 47.7 | 16,348 | 0.6 | 21 | 534 | 17.1 | 5,841 | 0.7 | 34 |
| 75-84 | 1,047 | 30.0 | 11,219 | 0.7 | 34 | 1,753 | 50.2 | 19,220 | 0.7 | 21 | 680 | 19.5 | 7,073 | 0.7 | 34 |
| 85 and older | 536 | 21.9 | 5,464 | 0.7 | 30 | 1,043 | 42.6 | 10,819 | 0.7 | 22 | 383 | 15.6 | 3,669 | 0.7 | 31 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 100.0 | 12 | 0.1 | 2 |

Table D7B

Dual Eligible Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table D.7B includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 - b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.7C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | ANTHYPERLIPIDEMIC | | | | | ANALGESICS - Narcotic | | | | | CALCIUM BLOCKERS | | | | |
|-----------------------------|-------------------|--------------------------|-----------------------------|----------------|-------------|-----------------------|--------------------------|-----------------------------|----------------|-------------|------------------|--------------------------|-----------------------------|----------------|-------------|
| | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ |
| All | 19,228 | 18.1 % | 220,473 | 0.6 | \$50 | 72,915 | 68.5 % | 823,100 | 0.4 | \$13 | 23,889 | 22.4 % | 268,410 | 0.7 | \$33 |
| Female | 14,684 | 19.9 | 168,731 | 0.6 | 50 | 54,752 | 74.3 | 621,002 | 0.4 | 13 | 18,736 | 25.4 | 211,281 | 0.7 | 34 |
| Disabled | 8,641 | 23.3 | 100,088 | 0.6 | 49 | 34,289 | 92.4 | 395,536 | 0.4 | 13 | 8,961 | 24.1 | 103,161 | 0.7 | 34 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 50.0 | 6 | 0.2 | 1 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 9.1 | 12 | 0.1 | 1 | 4 | 36.4 | 43 | 0.7 | 64 |
| 15-20 | 3 | 2.6 | 36 | 0.2 | 18 | 65 | 57.0 | 748 | 0.2 | 3 | 8 | 7.0 | 96 | 0.4 | 35 |
| 21-44 | 680 | 7.6 | 7,701 | 0.5 | 37 | 8,571 | 95.6 | 98,377 | 0.3 | 12 | 793 | 8.8 | 8,984 | 0.5 | 27 |
| 45-64 | 3,845 | 27.8 | 44,172 | 0.6 | 47 | 13,961 | 101.1 | 160,839 | 0.4 | 15 | 3,337 | 24.2 | 38,247 | 0.7 | 33 |
| 65-74 | 2,975 | 34.1 | 34,929 | 0.7 | 54 | 7,627 | 87.4 | 88,776 | 0.4 | 11 | 2,983 | 34.2 | 34,669 | 0.7 | 36 |
| 75-84 | 989 | 24.0 | 11,525 | 0.7 | 53 | 3,197 | 77.4 | 37,057 | 0.4 | 10 | 1,422 | 34.4 | 16,484 | 0.7 | 34 |
| 85 and older | 149 | 11.0 | 1,725 | 0.7 | 51 | 866 | 64.1 | 9,721 | 0.4 | 11 | 414 | 30.7 | 4,638 | 0.8 | 34 |
| Other Eligibles | 6,043 | 16.5 | 68,643 | 0.7 | 51 | 20,463 | 55.9 | 225,466 | 0.4 | 12 | 9,775 | 26.7 | 108,120 | 0.8 | 33 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 4 | 100.0 | 47 | 0.1 | 1 | 0 | 0.0 | 0 | 0.0 | 0 |
| 21-44 | 12 | 1.9 | 115 | 0.5 | 35 | 262 | 42.1 | 2,523 | 0.3 | 13 | 23 | 3.7 | 195 | 0.5 | 23 |
| 45-64 | 18 | 17.8 | 194 | 0.5 | 47 | 93 | 92.1 | 944 | 0.3 | 11 | 18 | 17.8 | 185 | 0.5 | 25 |
| 65-74 | 1,808 | 26.4 | 20,655 | 0.6 | 50 | 3,885 | 56.7 | 43,496 | 0.3 | 10 | 1,832 | 26.7 | 20,577 | 0.7 | 34 |
| 75-84 | 2,980 | 21.2 | 34,088 | 0.7 | 53 | 8,447 | 60.0 | 94,943 | 0.4 | 12 | 4,191 | 29.8 | 47,137 | 0.8 | 34 |
| 85 and older | 1,225 | 8.2 | 13,591 | 0.7 | 50 | 7,772 | 51.9 | 83,513 | 0.4 | 13 | 3,711 | 24.8 | 40,026 | 0.8 | 33 |
| Male | 4,544 | 13.9 | 51,742 | 0.6 | 48 | 18,161 | 55.6 | 202,074 | 0.4 | 14 | 5,153 | 15.8 | 57,129 | 0.7 | 33 |
| Disabled | 3,424 | 14.5 | 39,367 | 0.6 | 47 | 14,003 | 59.5 | 158,161 | 0.4 | 15 | 3,384 | 14.4 | 38,095 | 0.7 | 33 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 25.0 | 12 | 0.1 | 0 | 2 | 50.0 | 24 | 0.7 | 34 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 5 | 55.6 | 60 | 0.4 | 36 |
| 15-20 | 1 | 0.7 | 12 | 0.1 | 5 | 54 | 39.7 | 616 | 0.2 | 5 | 13 | 9.6 | 101 | 0.6 | 48 |
| 21-44 | 716 | 7.3 | 8,233 | 0.5 | 37 | 5,452 | 55.9 | 61,537 | 0.4 | 16 | 682 | 7.0 | 7,590 | 0.6 | 31 |
| 45-64 | 1,616 | 19.0 | 18,433 | 0.6 | 48 | 5,262 | 62.0 | 59,166 | 0.4 | 17 | 1,430 | 16.8 | 16,007 | 0.7 | 33 |
| 65-74 | 879 | 22.9 | 10,210 | 0.7 | 54 | 2,477 | 64.5 | 28,382 | 0.4 | 13 | 943 | 24.6 | 10,786 | 0.7 | 35 |
| 75-84 | 191 | 17.8 | 2,247 | 0.6 | 52 | 637 | 59.5 | 7,243 | 0.3 | 8 | 257 | 24.0 | 2,965 | 0.7 | 30 |
| 85 and older | 21 | 8.8 | 232 | 0.6 | 47 | 120 | 50.2 | 1,205 | 0.4 | 13 | 52 | 21.8 | 562 | 0.8 | 34 |
| Other Eligibles | 1,120 | 12.2 | 12,375 | 0.6 | 51 | 4,158 | 45.4 | 43,913 | 0.3 | 11 | 1,769 | 19.3 | 19,034 | 0.7 | 33 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 100.0 | 12 | 0.1 | 1 | 1 | 100.0 | 12 | 0.9 | 52 |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 21-44 | 4 | 7.5 | 40 | 0.9 | 79 | 60 | 113.2 | 460 | 0.6 | 42 | 4 | 7.5 | 25 | 0.6 | 20 |
| 45-64 | 4 | 12.9 | 37 | 0.5 | 36 | 29 | 93.5 | 248 | 0.5 | 16 | 4 | 12.9 | 37 | 0.4 | 19 |
| 65-74 | 479 | 15.3 | 5,255 | 0.6 | 49 | 1,372 | 43.8 | 15,046 | 0.3 | 10 | 561 | 17.9 | 6,077 | 0.7 | 32 |
| 75-84 | 473 | 13.6 | 5,295 | 0.7 | 55 | 1,591 | 45.6 | 16,980 | 0.4 | 11 | 750 | 21.5 | 8,173 | 0.7 | 34 |
| 85 and older | 160 | 6.5 | 1,748 | 0.6 | 47 | 1,105 | 45.1 | 11,167 | 0.3 | 12 | 449 | 18.3 | 4,710 | 0.8 | 32 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 2 | 200.0 | 24 | 0.1 | 1 | 0 | 0.0 | 0 | 0.0 | 0 |

Table D7C

Dual Eligible Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table D.7C includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 - b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.7D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | ULCER DRUGS | | | | ANTI-ASTHMATIC | | | | Mean Rx \$ | Mean No. of Rx | Users as % of Dual Benes | No. of Bene Mos among Users | Mean Rx \$ | Mean No. of Rx | Users as % of Dual Benes | No. of Bene Mos among Users | No. of Bene Mos |
|-----------------------------|---------------|--------------------------|-----------------------------|------------|----------------|--------------------------|-----------------------------|----------------|------------|----------------|--------------------------|-----------------------------|------------|----------------|--------------------------|-----------------------------|-----------------|
| | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean Rx \$ | Mean No. of Rx | Users as % of Dual Benes | No. of Bene Mos among Users | Mean Rx \$ | | | | | | | | | |
| All | 41,292 | 38.8 % | 465,304 | 0.5 | \$19 | 33,026 | 31.0 % | 367,008 | 0.4 | \$20 | 106,428 | 1,144,370 | | | | | |
| Female | | | | | | | | | | | | | | | | | |
| Disabled | 31,336 | 42.5 | 354,053 | 0.5 | 19 | 23,663 | 32.1 | 264,563 | 0.4 | 19 | 73,739 | 798,018 | | | | | |
| 5 and younger | 17,103 | 46.1 | 197,866 | 0.4 | 18 | 14,523 | 39.1 | 166,365 | 0.4 | 20 | 37,108 | 413,555 | | | | | |
| 6-14 | 4 | 200.0 | 30 | 0.2 | 24 | 0 | 0.0 | 0 | 0.0 | 0 | 2 | 18 | | | | | |
| 15-20 | 4 | 36.4 | 48 | 0.5 | 26 | 1 | 9.1 | 12 | 0.5 | 12 | 11 | 119 | | | | | |
| 21-44 | 17 | 14.9 | 194 | 0.2 | 21 | 25 | 21.9 | 290 | 0.4 | 19 | 114 | 1,256 | | | | | |
| 45-64 | 2,962 | 33.0 | 34,231 | 0.3 | 15 | 2,570 | 28.7 | 29,416 | 0.3 | 16 | 8,963 | 99,054 | | | | | |
| 65-74 | 7,082 | 51.3 | 81,924 | 0.4 | 19 | 6,479 | 46.9 | 74,132 | 0.4 | 21 | 13,813 | 151,584 | | | | | |
| 75-84 | 4,589 | 52.6 | 53,519 | 0.5 | 19 | 3,878 | 44.4 | 44,632 | 0.4 | 23 | 8,726 | 100,067 | | | | | |
| 85 and older | 1,847 | 44.7 | 21,263 | 0.5 | 18 | 1,272 | 30.8 | 14,583 | 0.4 | 20 | 4,129 | 46,858 | | | | | |
| Other Eligibles | 598 | 44.3 | 6,657 | 0.5 | 19 | 298 | 22.1 | 3,300 | 0.4 | 18 | 1,350 | 14,599 | | | | | |
| 5 and younger | 14,233 | 38.9 | 156,187 | 0.5 | 20 | 9,140 | 25.0 | 98,198 | 0.4 | 17 | 36,631 | 384,463 | | | | | |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 | | | | | |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 | | | | | |
| 21-44 | 71 | 11.4 | 694 | 0.3 | 13 | 73 | 11.7 | 650 | 0.3 | 15 | 622 | 5,866 | | | | | |
| 45-64 | 41 | 40.6 | 431 | 0.3 | 11 | 32 | 31.7 | 305 | 0.5 | 23 | 101 | 873 | | | | | |
| 65-74 | 2,309 | 33.7 | 25,989 | 0.4 | 18 | 1,680 | 24.5 | 18,630 | 0.4 | 20 | 6,857 | 73,214 | | | | | |
| 75-84 | 5,732 | 40.7 | 64,033 | 0.5 | 20 | 3,678 | 26.1 | 40,040 | 0.4 | 19 | 14,084 | 151,869 | | | | | |
| 85 and older | 6,080 | 40.6 | 65,040 | 0.6 | 21 | 3,677 | 24.6 | 38,573 | 0.4 | 15 | 14,963 | 152,594 | | | | | |
| Male | | | | | | | | | | | | | | | | | |
| Disabled | 9,956 | 30.5 | 111,251 | 0.5 | 19 | 9,363 | 28.6 | 102,445 | 0.4 | 21 | 32,688 | 346,340 | | | | | |
| 5 and younger | 6,862 | 29.2 | 78,436 | 0.4 | 19 | 6,154 | 26.1 | 69,320 | 0.5 | 22 | 23,535 | 254,909 | | | | | |
| 6-14 | 6 | 150.0 | 72 | 0.5 | 27 | 4 | 100.0 | 48 | 0.2 | 18 | 4 | 48 | | | | | |
| 15-20 | 4 | 44.4 | 48 | 0.4 | 34 | 4 | 44.4 | 48 | 0.3 | 18 | 9 | 93 | | | | | |
| 21-44 | 10 | 7.4 | 111 | 0.3 | 11 | 23 | 16.9 | 276 | 0.7 | 32 | 136 | 1,478 | | | | | |
| 45-64 | 1,989 | 20.4 | 22,887 | 0.4 | 16 | 1,320 | 13.5 | 14,853 | 0.3 | 17 | 9,748 | 105,343 | | | | | |
| 65-74 | 2,852 | 33.6 | 32,355 | 0.5 | 21 | 2,362 | 27.8 | 26,584 | 0.4 | 22 | 8,488 | 90,220 | | | | | |
| 75-84 | 1,517 | 39.5 | 17,432 | 0.5 | 19 | 1,916 | 49.9 | 21,754 | 0.5 | 26 | 3,840 | 43,206 | | | | | |
| 85 and older | 403 | 37.6 | 4,637 | 0.5 | 18 | 435 | 40.6 | 4,856 | 0.5 | 20 | 1,071 | 11,965 | | | | | |
| Other Eligibles | 81 | 33.9 | 894 | 0.5 | 15 | 90 | 37.7 | 901 | 0.4 | 13 | 239 | 2,556 | | | | | |
| 5 and younger | 3,094 | 33.8 | 32,815 | 0.5 | 20 | 3,209 | 35.1 | 33,125 | 0.4 | 19 | 9,153 | 91,431 | | | | | |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 | | | | | |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 12 | | | | | |
| 21-44 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 7 | | | | | |
| 45-64 | 18 | 34.0 | 148 | 0.4 | 18 | 11 | 20.8 | 94 | 0.3 | 13 | 53 | 368 | | | | | |
| 65-74 | 7 | 22.6 | 66 | 0.5 | 23 | 12 | 38.7 | 110 | 0.3 | 13 | 31 | 278 | | | | | |
| 75-84 | 921 | 29.4 | 9,984 | 0.5 | 19 | 971 | 31.0 | 10,397 | 0.5 | 22 | 3,130 | 31,975 | | | | | |
| 85 and older | 1,214 | 34.8 | 13,061 | 0.5 | 20 | 1,289 | 36.9 | 13,386 | 0.4 | 19 | 3,489 | 35,457 | | | | | |
| Unknown | 934 | 38.2 | 9,556 | 0.6 | 21 | 926 | 37.8 | 9,138 | 0.4 | 17 | 2,448 | 23,334 | | | | | |
| | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 12 | | | | | |

Table D7D

Dual Eligible Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table D.7D includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE D.8
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BENEFICIARY CHARACTERISTIC^{a, b}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | Rx \$ per Bene Mo | No. of Rx per Bene Mo | No. of All-Year NF Residents | Bene Mos among All-Year NF Residents |
|---|-------------------|-----------------------|------------------------------|--------------------------------------|
| All | \$285 | 6.5 | 17,137 | 170,983 |
| Age | | | | |
| 0-64 | 335 | 6.6 | 1,149 | 12,384 |
| 65-74 | 343 | 7.2 | 2,137 | 21,999 |
| 75-84 | 305 | 6.9 | 5,581 | 55,663 |
| 85 and older | 248 | 6.0 | 8,270 | 80,937 |
| Unknown | 0 | 0.0 | 0 | 0 |
| Gender | | | | |
| Female | 284 | 6.6 | 13,413 | 134,793 |
| Male | 291 | 6.3 | 3,724 | 36,190 |
| Unknown | 0 | 0.0 | 0 | 0 |
| Race | | | | |
| White | 295 | 6.8 | 12,983 | 128,054 |
| African American | 256 | 5.5 | 4,032 | 41,721 |
| Other/unknown | 245 | 5.7 | 122 | 1,208 |
| Basis of Eligibility^c | | | | |
| Aged | 277 | 6.5 | 14,231 | 139,358 |
| Disabled | 319 | 6.7 | 2,906 | 31,625 |
| Adults | 0 | 0.0 | 0 | 0 |
| Children | 0 | 0.0 | 0 | 0 |
| Unknown | 0 | 0.0 | 0 | 0 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table D.8 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their 2002 Medicaid enrollment. A total of 6,886 beneficiaries who were in nursing facilities for part of their enrollment and their 67,252 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE D.9
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Therapeutic Category | No. of Rx per Bene Mo among Users | | | \$ per Bene Mo among Users | | | Total # of Rx | Total Rx \$ | No. Residents | As % of Dual All-Year NF Residents | No. of Bene Mos | | | | | | |
|---|-----------------------------------|----------|------------|----------------------------|---------|-------|---------------|-------------|---------------|------------------------------------|-----------------|----------|------------|-------------|---------|--------|---------|
| | Total | Patented | Off-Patent | Brand-Name | Generic | Total | | | | | | Patented | Off-Patent | Brand-Name | Generic | | |
| Anti-infective Agents | 0.3 | 0.2 | 0.0 | 0.1 | \$20 | \$17 | \$1 | \$2 | \$58 | \$87 | \$74 | \$15 | 44,860 | \$2,618,888 | 12,246 | 71.5 % | 129,757 |
| Biologics | 0.1 | 0.1 | 0.0 | 0.0 | 1 | 1 | 0 | 0 | 14 | 12 | 0 | 22 | 2,856 | 39,104 | 2,596 | 15.1 | 29,558 |
| Antineoplastic Agents | 0.5 | 0.1 | 0.1 | 0.3 | 75 | 16 | 22 | 38 | 157 | 239 | 236 | 117 | 11,322 | 1,773,662 | 2,378 | 13.9 | 23,536 |
| Endocrine/Metabolic Drugs | 1.1 | 0.5 | 0.1 | 0.5 | 41 | 33 | 2 | 6 | 38 | 62 | 23 | 13 | 95,521 | 3,642,112 | 8,461 | 49.4 | 88,420 |
| Cardiovascular Agents | 2.0 | 0.5 | 0.2 | 1.3 | 51 | 25 | 6 | 19 | 25 | 52 | 26 | 15 | 261,533 | 6,663,921 | 12,882 | 75.2 | 131,700 |
| Respiratory Agents | 0.6 | 0.2 | 0.0 | 0.3 | 19 | 12 | 1 | 6 | 34 | 63 | 33 | 19 | 49,452 | 1,680,289 | 8,190 | 47.8 | 87,267 |
| Gastrointestinal Agents | 1.0 | 0.2 | 0.0 | 0.8 | 32 | 16 | 1 | 16 | 34 | 89 | 67 | 21 | 89,016 | 3,024,977 | 8,909 | 52.0 | 93,567 |
| Genitourinary Agents | 0.6 | 0.4 | 0.0 | 0.1 | 32 | 29 | 1 | 2 | 56 | 69 | 32 | 19 | 24,352 | 1,372,054 | 3,966 | 23.1 | 42,643 |
| CNS Drugs | 1.4 | 0.9 | 0.1 | 0.5 | 100 | 83 | 7 | 10 | 71 | 98 | 70 | 21 | 174,364 | 12,316,103 | 11,877 | 69.3 | 122,873 |
| Stimulants/Anti-obesity/Anorexia | 0.5 | 0.1 | 0.0 | 0.4 | 26 | 17 | 2 | 7 | 47 | 149 | 44 | 19 | 587 | 27,836 | 108 | 0.6 | 1,074 |
| Miscellaneous Psychological/Neurological Agents | 0.8 | 0.8 | 0.0 | 0.0 | 94 | 93 | 0 | 0 | 121 | 123 | 0 | 23 | 28,207 | 3,422,317 | 3,552 | 20.7 | 36,557 |
| Analgesics and Anesthetics | 0.8 | 0.2 | 0.1 | 0.5 | 33 | 22 | 3 | 8 | 43 | 114 | 46 | 16 | 69,623 | 2,966,211 | 8,585 | 50.1 | 89,125 |
| Neuromuscular Agents | 1.1 | 0.4 | 0.2 | 0.5 | 55 | 34 | 7 | 14 | 50 | 76 | 45 | 28 | 67,166 | 3,357,413 | 5,766 | 33.6 | 61,118 |
| Nutritional Products | 0.8 | 0.0 | 0.1 | 0.7 | 12 | 1 | 2 | 10 | 14 | 25 | 20 | 13 | 73,942 | 1,053,858 | 8,583 | 50.1 | 89,015 |
| Hematological Agents | 1.0 | 0.3 | 0.2 | 0.4 | 44 | 35 | 4 | 5 | 47 | 117 | 16 | 13 | 61,051 | 2,846,524 | 6,185 | 36.1 | 64,104 |
| Topical Products | 0.5 | 0.2 | 0.0 | 0.2 | 17 | 11 | 2 | 4 | 34 | 51 | 42 | 18 | 52,852 | 1,819,628 | 10,066 | 58.7 | 108,737 |
| Miscellaneous Products | 0.3 | 0.1 | 0.0 | 0.2 | 9 | 2 | 0 | 7 | 34 | 33 | 50 | 34 | 2,282 | 76,501 | 835 | 4.9 | 8,708 |
| Unknown Therapeutic Category | 0.2 | 0.0 | 0.0 | 0.0 | 4 | 0 | 0 | 0 | 21 | 0 | 0 | 0 | 1,989 | 41,904 | 915 | 5.3 | 9,749 |
| TOTAL NO. OF RX AND RX \$ | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 1,110,975 | 48,743,302 | n.a. | n.a. | n.a. |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table D.9 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 6,886 beneficiaries who were in nursing facilities for part of their enrollment and their 67,252 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2002. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003). In Alabama, 0.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.10
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
 BY TOP-10 DRUG GROUP^{a, b, c, d}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Top 10 Drug Groups in Nursing Facilities | Users | | | | Among Users | | |
|--|----------------------|---------------|-------------------------------|-----------------|-----------------------|-------------|-------------------|
| | Total Medicaid Rx \$ | No. of Users | As % of All-Year NF Residents | No. of Bene Mos | No. of Rx per Bene Mo | \$ per Rx | Rx \$ per Bene Mo |
| ANTIPSYCHOTICS | \$6,055,960 | 6,162 | 36.0 % | 64,997 | 0.7 | \$129 | \$93 |
| ANTIDEPRESSANTS | 5,419,179 | 11,148 | 65.1 | 118,572 | 0.8 | 59 | 46 |
| MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL | 3,411,259 | 3,416 | 19.9 | 35,916 | 0.8 | 121 | 95 |
| ANTICONVULSANT | 2,540,381 | 5,191 | 30.3 | 55,950 | 0.9 | 53 | 45 |
| ANTIDIABETIC | 2,401,915 | 6,346 | 37.0 | 67,609 | 0.8 | 42 | 36 |
| ULCER DRUGS | 2,246,772 | 8,289 | 48.4 | 88,761 | 0.7 | 37 | 25 |
| ANALGESICS - Narcotic | 1,995,981 | 8,553 | 49.9 | 89,870 | 0.5 | 46 | 22 |
| ANTIHYPERTENSIVE | 1,985,634 | 7,493 | 43.7 | 78,738 | 0.8 | 32 | 25 |
| ANTINEOPLASTICS | 1,770,397 | 2,395 | 14.0 | 23,870 | 0.5 | 157 | 74 |
| MISC. HEMATOLOGICAL | 1,734,547 | 2,641 | 15.4 | 27,929 | 0.7 | 86 | 62 |
| Total | 29,562,025 | 61,634 | | 652,212 | n.a. | n.a. | n.a. |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table D.10 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 6,886 beneficiaries who were in nursing facilities for part of their enrollment and their 67,252 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | All Top 10 Drug Groups | | | | | | ANTIPSYCHOTICS | | | | | | ANTIDEPRESSANTS | | | | | |
|-----------------------------|------------------------|---------------------|--------------|---------------|---------------|------------|----------------|----------------|-----------------------------|----------------------------------|-----------------------------|----------------------------------|-----------------|----------------|-----------------------------|----------------------------------|------------|----------------|
| | No. of Rx | Rx \$ | No. of Users | Users as % | | | Mean Rx \$ | Mean No. of Rx | No. of Bene Mos among Users | Users as % of All-Year Residents | No. of Bene Mos among Users | Users as % of All-Year Residents | Mean Rx \$ | Mean No. of Rx | No. of Bene Mos among Users | Users as % of All-Year Residents | Mean Rx \$ | Mean No. of Rx |
| | | | | 36.0 % | 64,997 | 0.7 | | | | | | | | | | | | |
| All | 471,980 | \$29,562,025 | 6,162 | 36.0 % | 64,997 | 0.7 | \$93 | 11,148 | 65.1 % | 118,572 | 0.8 | \$46 | | | | | | |
| Female | 371,202 | 23,051,053 | 4,722 | 35.2 | 50,032 | 0.7 | 92 | 8,883 | 66.2 | 94,824 | 0.8 | 46 | | | | | | |
| Disabled | 60,922 | 4,098,329 | 762 | 43.4 | 8,602 | 0.8 | 117 | 1,205 | 68.7 | 13,454 | 0.8 | 51 | | | | | | |
| 64 or younger | 19,583 | 1,389,022 | 202 | 37.3 | 2,263 | 0.9 | 129 | 395 | 73.0 | 4,368 | 0.8 | 51 | | | | | | |
| 65-74 | 19,948 | 1,339,666 | 239 | 46.9 | 2,763 | 0.8 | 134 | 357 | 70.0 | 4,080 | 0.8 | 53 | | | | | | |
| 75-84 | 14,002 | 924,154 | 226 | 52.4 | 2,552 | 0.8 | 103 | 292 | 67.7 | 3,254 | 0.8 | 53 | | | | | | |
| 85 and older | 7,389 | 445,487 | 95 | 34.9 | 1,024 | 0.6 | 83 | 161 | 59.2 | 1,752 | 0.7 | 44 | | | | | | |
| Other Eligibles | 310,280 | 18,952,724 | 3,960 | 34.0 | 41,430 | 0.7 | 87 | 7,678 | 65.9 | 81,370 | 0.8 | 45 | | | | | | |
| 64 or younger | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | | |
| 65-74 | 28,447 | 1,861,074 | 361 | 45.7 | 3,833 | 0.8 | 109 | 627 | 79.4 | 6,607 | 0.8 | 48 | | | | | | |
| 75-84 | 121,038 | 7,442,334 | 1,558 | 39.5 | 16,533 | 0.7 | 92 | 2,892 | 73.3 | 30,832 | 0.8 | 45 | | | | | | |
| 85 and older | 160,795 | 9,649,316 | 2,041 | 29.5 | 21,064 | 0.7 | 80 | 4,159 | 60.1 | 43,931 | 0.8 | 44 | | | | | | |
| Male | 100,778 | 6,510,972 | 1,440 | 38.7 | 14,965 | 0.7 | 96 | 2,265 | 60.8 | 23,748 | 0.8 | 46 | | | | | | |
| Disabled | 35,806 | 2,371,913 | 464 | 40.3 | 5,149 | 0.8 | 113 | 678 | 58.9 | 7,612 | 0.8 | 48 | | | | | | |
| 64 or younger | 19,102 | 1,299,981 | 264 | 43.4 | 2,883 | 0.8 | 115 | 364 | 59.9 | 4,082 | 0.8 | 49 | | | | | | |
| 65-74 | 11,156 | 736,683 | 132 | 38.5 | 1,504 | 0.8 | 114 | 202 | 58.9 | 2,240 | 0.8 | 49 | | | | | | |
| 75-84 | 4,219 | 244,295 | 52 | 35.4 | 591 | 0.8 | 95 | 86 | 58.5 | 982 | 0.8 | 44 | | | | | | |
| 85 and older | 1,329 | 90,954 | 16 | 29.6 | 171 | 1.0 | 135 | 26 | 48.1 | 308 | 0.8 | 46 | | | | | | |
| Other Eligibles | 64,972 | 4,139,059 | 976 | 37.9 | 9,816 | 0.7 | 87 | 1,587 | 61.7 | 16,136 | 0.8 | 46 | | | | | | |
| 64 or younger | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | | |
| 65-74 | 14,991 | 942,950 | 199 | 40.3 | 2,116 | 0.7 | 95 | 350 | 70.9 | 3,613 | 0.8 | 46 | | | | | | |
| 75-84 | 28,393 | 1,795,592 | 426 | 40.4 | 4,340 | 0.7 | 92 | 678 | 64.3 | 7,056 | 0.8 | 46 | | | | | | |
| 85 and older | 21,588 | 1,400,517 | 351 | 34.3 | 3,360 | 0.6 | 77 | 559 | 54.6 | 5,467 | 0.8 | 45 | | | | | | |
| Unknown | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | | |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table D.10A includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 6,886 beneficiaries who were in nursing facilities for part of their enrollment and their 67,252 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.10B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL | | | | | | ANTICONVULSANT | | | | | | ANTIDIABETIC | | | | | | |
|-----------------------------|---|-----------------------------|----------------|--------------|-----------------------------|----------------|----------------|-----------------------------|----------------|---------------|-----------------------------|----------------|---------------|-----------------------------|----------------|--------------|-----------------------------|----------------|-------------|
| | Users as % | | | Users as % | | | Users as % | | | Users as % | | | Users as % | | | Users as % | | | |
| | No. of Users | No. of Bene Mos among Users | Mean No. of Rx | No. of Users | No. of Bene Mos among Users | Mean No. of Rx | No. of Users | No. of Bene Mos among Users | Mean No. of Rx | No. of Users | No. of Bene Mos among Users | Mean No. of Rx | No. of Users | No. of Bene Mos among Users | Mean No. of Rx | No. of Users | No. of Bene Mos among Users | Mean No. of Rx | |
| All | 3,416 | 19.9 % | \$95 | 5,191 | 30.3 % | \$45 | 6,346 | 37.0 % | \$45 | 67,609 | 0.8 | 6,346 | 37.0 % | \$45 | 67,609 | 0.8 | 6,346 | 37.0 % | \$36 |
| Female | 2,796 | 20.8 | 94 | 3,779 | 28.2 | 44 | 5,022 | 37.4 | 44 | 53,579 | 0.8 | 5,022 | 37.4 | 44 | 53,579 | 0.9 | 5,022 | 37.4 | 36 |
| Disabled | 210 | 12.0 | 96 | 921 | 52.5 | 59 | 852 | 48.6 | 59 | 9,604 | 0.9 | 852 | 48.6 | 59 | 9,604 | 0.9 | 852 | 48.6 | 40 |
| 64 or younger | 30 | 5.5 | 103 | 432 | 79.9 | 69 | 228 | 42.1 | 69 | 2,571 | 1.0 | 228 | 42.1 | 69 | 2,571 | 1.0 | 228 | 42.1 | 40 |
| 65-74 | 60 | 11.8 | 103 | 293 | 57.5 | 56 | 307 | 60.2 | 56 | 3,547 | 0.9 | 307 | 60.2 | 56 | 3,547 | 0.9 | 307 | 60.2 | 44 |
| 75-84 | 78 | 18.1 | 90 | 140 | 32.5 | 44 | 205 | 47.6 | 44 | 2,298 | 0.8 | 205 | 47.6 | 44 | 2,298 | 0.8 | 205 | 47.6 | 35 |
| 85 and older | 42 | 15.4 | 91 | 56 | 20.6 | 37 | 112 | 41.2 | 37 | 1,188 | 0.8 | 112 | 41.2 | 37 | 1,188 | 0.8 | 112 | 41.2 | 33 |
| Other Eligibles | 2,586 | 22.2 | 94 | 2,858 | 24.5 | 38 | 4,170 | 35.8 | 38 | 43,975 | 0.8 | 4,170 | 35.8 | 38 | 43,975 | 0.8 | 4,170 | 35.8 | 35 |
| 64 or younger | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 65-74 | 171 | 21.6 | 97 | 339 | 42.9 | 48 | 481 | 60.9 | 48 | 5,040 | 0.9 | 481 | 60.9 | 48 | 5,040 | 0.9 | 481 | 60.9 | 39 |
| 75-84 | 984 | 24.9 | 95 | 1,241 | 31.4 | 39 | 1,706 | 43.2 | 39 | 18,204 | 0.9 | 1,706 | 43.2 | 39 | 18,204 | 0.9 | 1,706 | 43.2 | 37 |
| 85 and older | 1,431 | 20.7 | 94 | 1,278 | 18.5 | 35 | 1,983 | 28.7 | 35 | 20,731 | 0.8 | 1,983 | 28.7 | 35 | 20,731 | 0.8 | 1,983 | 28.7 | 32 |
| Male | 620 | 16.6 | 98 | 1,412 | 37.9 | 50 | 1,324 | 35.6 | 50 | 14,030 | 0.8 | 1,324 | 35.6 | 50 | 14,030 | 0.8 | 1,324 | 35.6 | 35 |
| Disabled | 112 | 9.7 | 102 | 652 | 56.6 | 59 | 432 | 37.5 | 59 | 4,855 | 0.8 | 432 | 37.5 | 59 | 4,855 | 0.8 | 432 | 37.5 | 35 |
| 64 or younger | 42 | 6.9 | 107 | 403 | 66.3 | 65 | 209 | 34.4 | 65 | 2,296 | 0.8 | 209 | 34.4 | 65 | 2,296 | 0.8 | 209 | 34.4 | 37 |
| 65-74 | 45 | 13.1 | 98 | 181 | 52.8 | 51 | 149 | 43.4 | 51 | 1,736 | 0.8 | 149 | 43.4 | 51 | 1,736 | 0.8 | 149 | 43.4 | 36 |
| 75-84 | 16 | 10.9 | 96 | 50 | 34.0 | 49 | 69 | 46.9 | 49 | 783 | 0.8 | 69 | 46.9 | 49 | 783 | 0.8 | 69 | 46.9 | 29 |
| 85 and older | 9 | 16.7 | 112 | 18 | 33.3 | 50 | 5 | 9.3 | 50 | 40 | 0.8 | 5 | 9.3 | 50 | 40 | 0.8 | 5 | 9.3 | 31 |
| Other Eligibles | 508 | 19.8 | 97 | 760 | 29.5 | 41 | 892 | 34.7 | 41 | 9,175 | 0.8 | 892 | 34.7 | 41 | 9,175 | 0.8 | 892 | 34.7 | 36 |
| 64 or younger | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 65-74 | 71 | 14.4 | 100 | 207 | 41.9 | 45 | 206 | 41.7 | 45 | 2,142 | 0.9 | 206 | 41.7 | 45 | 2,142 | 0.9 | 206 | 41.7 | 36 |
| 75-84 | 227 | 21.5 | 91 | 349 | 33.1 | 41 | 420 | 39.8 | 41 | 4,358 | 0.8 | 420 | 39.8 | 41 | 4,358 | 0.8 | 420 | 39.8 | 37 |
| 85 and older | 210 | 20.5 | 103 | 204 | 19.9 | 35 | 266 | 26.0 | 35 | 2,675 | 0.8 | 266 | 26.0 | 35 | 2,675 | 0.8 | 266 | 26.0 | 33 |
| Unknown | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table D.10B includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 6,886 beneficiaries who were in nursing facilities for part of their enrollment and their 67,252 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.10C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | ULCER DRUGS | | | | | | ANALGESICS - Narcotic | | | | | | ANTIHYPERTENSIVE | | | | | | |
|-----------------------------|--------------|-------------------------|----------------|-------------|--------------|----------------|-------------------------|----------------|-------------|--------------|----------------|-------------------------|------------------|-------------|--------------|----------------|-------------------------|----------------|------------|
| | Users as % | | | Users as % | | | Users as % | | | Users as % | | | Users as % | | | Users as % | | | |
| | No. of Users | No. of Bene among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Mean No. of Rx | No. of Bene among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Mean No. of Rx | No. of Bene among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Mean No. of Rx | No. of Bene among Users | Mean No. of Rx | Mean Rx \$ |
| All | 8,289 | 48.4 % | 0.7 | \$25 | 8,553 | 49.9 % | 89,870 | 0.5 | \$22 | 7,493 | 43.7 % | 78,738 | 0.8 | \$25 | | | | | |
| Female | 6,507 | 48.5 | 0.7 | 25 | 6,912 | 51.5 | 73,168 | 0.5 | 23 | 5,800 | 43.2 | 61,025 | 0.8 | 25 | | | | | |
| Disabled | 925 | 52.7 | 0.7 | 26 | 920 | 52.5 | 10,307 | 0.5 | 28 | 783 | 44.6 | 8,685 | 0.8 | 27 | | | | | |
| 64 or younger | 283 | 52.3 | 0.7 | 30 | 253 | 46.8 | 2,757 | 0.6 | 33 | 204 | 37.7 | 2,227 | 0.8 | 26 | | | | | |
| 65-74 | 282 | 55.3 | 0.7 | 25 | 297 | 58.2 | 3,381 | 0.6 | 30 | 237 | 46.5 | 2,690 | 0.8 | 28 | | | | | |
| 75-84 | 211 | 49.0 | 0.7 | 24 | 219 | 50.8 | 2,495 | 0.5 | 23 | 200 | 46.4 | 2,259 | 0.8 | 26 | | | | | |
| 85 and older | 149 | 54.8 | 0.7 | 25 | 151 | 55.5 | 1,674 | 0.4 | 23 | 142 | 52.2 | 1,509 | 0.8 | 27 | | | | | |
| Other Eligibles | 5,582 | 47.9 | 0.7 | 25 | 5,992 | 51.4 | 62,861 | 0.5 | 22 | 5,017 | 43.0 | 52,340 | 0.8 | 25 | | | | | |
| 64 or younger | 0 | 0.0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 65-74 | 415 | 52.5 | 0.7 | 27 | 498 | 63.0 | 5,196 | 0.6 | 34 | 441 | 55.8 | 4,623 | 0.8 | 25 | | | | | |
| 75-84 | 1,926 | 48.8 | 0.7 | 25 | 2,140 | 54.2 | 22,731 | 0.5 | 23 | 1,914 | 48.5 | 20,084 | 0.8 | 26 | | | | | |
| 85 and older | 3,241 | 46.8 | 0.7 | 24 | 3,354 | 48.5 | 34,934 | 0.5 | 19 | 2,662 | 38.5 | 27,633 | 0.8 | 25 | | | | | |
| Male | 1,782 | 47.9 | 0.7 | 27 | 1,641 | 44.1 | 16,702 | 0.5 | 21 | 1,693 | 45.5 | 17,713 | 0.8 | 25 | | | | | |
| Disabled | 588 | 51.0 | 0.7 | 28 | 498 | 43.2 | 5,368 | 0.5 | 27 | 524 | 45.5 | 5,773 | 0.8 | 25 | | | | | |
| 64 or younger | 308 | 50.7 | 0.7 | 29 | 260 | 42.8 | 2,846 | 0.5 | 28 | 267 | 43.9 | 2,907 | 0.8 | 25 | | | | | |
| 65-74 | 186 | 54.2 | 0.7 | 27 | 142 | 41.4 | 1,529 | 0.5 | 30 | 173 | 50.4 | 1,908 | 0.8 | 27 | | | | | |
| 75-84 | 72 | 49.0 | 0.7 | 30 | 71 | 48.3 | 731 | 0.4 | 20 | 64 | 43.5 | 725 | 0.8 | 22 | | | | | |
| 85 and older | 22 | 40.7 | 0.8 | 22 | 25 | 46.3 | 262 | 0.5 | 25 | 20 | 37.0 | 233 | 0.8 | 24 | | | | | |
| Other Eligibles | 1,194 | 46.4 | 0.7 | 26 | 1,143 | 44.4 | 11,334 | 0.4 | 18 | 1,169 | 45.5 | 11,940 | 0.8 | 25 | | | | | |
| 64 or younger | 0 | 0.0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 65-74 | 250 | 50.6 | 0.7 | 27 | 242 | 49.0 | 2,496 | 0.5 | 21 | 264 | 53.4 | 2,728 | 0.8 | 25 | | | | | |
| 75-84 | 481 | 45.6 | 0.7 | 26 | 461 | 43.7 | 4,664 | 0.4 | 17 | 495 | 46.9 | 5,130 | 0.8 | 25 | | | | | |
| 85 and older | 463 | 45.3 | 0.7 | 26 | 440 | 43.0 | 4,174 | 0.4 | 18 | 410 | 40.1 | 4,082 | 0.8 | 25 | | | | | |
| Unknown | 0 | 0.0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table D.10C includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 6,886 beneficiaries who were in nursing facilities for part of their enrollment and their 67,252 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.10D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | ANTINEOPLASTICS | | | | | MISC. HEMATOLOGICAL | | | | | | |
|-----------------------------|-----------------|---------------|---------------|-----------------|-------------|---------------------|---------------|---------------|-----------------|-------------|---------------|----------------|
| | Users as % | | No. of Bene | | Mean Rx | Users as % | | No. of Bene | | Mean Rx \$ | | |
| | No. of Users | Residents | NF | Mos among Users | | No. of Users | Residents | NF | Mos among Users | | | |
| All | 2,395 | 14.0 % | 23,870 | 0.5 | \$74 | 2,641 | 15.4 % | 27,929 | 0.7 | \$62 | 17,137 | 170,983 |
| Female | 1,949 | 14.5 | 19,598 | 0.5 | 70 | 2,044 | 15.2 | 21,703 | 0.7 | 62 | 13,413 | 134,793 |
| Disabled | 204 | 11.6 | 2,195 | 0.5 | 100 | 250 | 14.3 | 2,806 | 0.7 | 58 | 1,754 | 19,165 |
| 64 or younger | 59 | 10.9 | 639 | 0.5 | 181 | 46 | 8.5 | 501 | 0.7 | 65 | 541 | 5,884 |
| 65-74 | 55 | 10.8 | 571 | 0.5 | 58 | 76 | 14.9 | 858 | 0.8 | 62 | 510 | 5,668 |
| 75-84 | 50 | 11.6 | 557 | 0.4 | 78 | 73 | 16.9 | 855 | 0.6 | 51 | 431 | 4,767 |
| 85 and older | 40 | 14.7 | 428 | 0.4 | 63 | 55 | 20.2 | 592 | 0.7 | 57 | 272 | 2,846 |
| Other Eligibles | 1,745 | 15.0 | 17,403 | 0.5 | 66 | 1,794 | 15.4 | 18,897 | 0.7 | 62 | 11,659 | 115,628 |
| 64 or younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 65-74 | 92 | 11.6 | 927 | 0.5 | 73 | 135 | 17.1 | 1,419 | 0.8 | 74 | 790 | 7,852 |
| 75-84 | 557 | 14.1 | 5,694 | 0.5 | 67 | 643 | 16.3 | 6,751 | 0.7 | 61 | 3,948 | 39,515 |
| 85 and older | 1,096 | 15.8 | 10,782 | 0.5 | 65 | 1,016 | 14.7 | 10,727 | 0.7 | 61 | 6,921 | 68,261 |
| Male | 446 | 12.0 | 4,272 | 0.4 | 94 | 597 | 16.0 | 6,226 | 0.8 | 64 | 3,724 | 36,190 |
| Disabled | 98 | 8.5 | 1,056 | 0.5 | 90 | 161 | 14.0 | 1,782 | 0.8 | 63 | 1,152 | 12,460 |
| 64 or younger | 40 | 6.6 | 452 | 0.5 | 95 | 63 | 10.4 | 703 | 0.7 | 65 | 608 | 6,500 |
| 65-74 | 35 | 10.2 | 362 | 0.4 | 98 | 72 | 21.0 | 783 | 0.7 | 60 | 343 | 3,775 |
| 75-84 | 17 | 11.6 | 174 | 0.4 | 54 | 19 | 12.9 | 219 | 0.8 | 65 | 147 | 1,574 |
| 85 and older | 6 | 11.1 | 68 | 0.6 | 106 | 7 | 13.0 | 77 | 0.9 | 80 | 54 | 611 |
| Other Eligibles | 348 | 13.5 | 3,216 | 0.4 | 95 | 436 | 17.0 | 4,444 | 0.8 | 64 | 2,572 | 23,730 |
| 64 or younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 65-74 | 58 | 11.7 | 603 | 0.4 | 108 | 98 | 19.8 | 1,026 | 0.8 | 69 | 494 | 4,704 |
| 75-84 | 147 | 13.9 | 1,414 | 0.5 | 79 | 172 | 16.3 | 1,828 | 0.7 | 59 | 1,055 | 9,807 |
| 85 and older | 143 | 14.0 | 1,199 | 0.4 | 107 | 166 | 16.2 | 1,590 | 0.8 | 66 | 1,023 | 9,219 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table D.10D includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 6,886 beneficiaries who were in nursing facilities for part of their enrollment and their 67,252 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.11
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG DUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}
 ALABAMA, 2002

| Beneficiary Characteristics | No. of Benes with at Least One Part D Excl Rx | % Benes with at Least One Part D Excl Rx | No. of Part D Excl Rx per Bene | | Total No. Part D Excl Rx | Total Part D Excl Rx \$ | \$ per Part D Excl Rx | Part D Excl Rx as % of All Dual Rx | Total No. of Benes |
|--|---|--|--------------------------------|----------------|--------------------------|-------------------------|-----------------------|------------------------------------|--------------------|
| | | | 45.7 % | 2.4 | | | | | |
| All | 48,627 | 45.7 % | 2.4 | 255,482 | \$70 | \$7,403,935 | \$29 | 3.4 % | 106,428 |
| Age | | | | | | | | | |
| 5 and younger | 5 | 83.3 | 2.5 | 15 | 179 | 1,072 | 71 | 2.5 | 6 |
| 6-14 | 7 | 33.3 | 0.7 | 14 | 54 | 1,124 | 80 | 0.7 | 21 |
| 15-20 | 81 | 31.8 | 1.0 | 250 | 44 | 11,269 | 45 | 2.8 | 255 |
| 21-44 | 7,415 | 38.2 | 2.0 | 38,342 | 60 | 1,166,085 | 30 | 3.5 | 19,387 |
| 45-64 | 10,929 | 48.7 | 3.0 | 66,442 | 75 | 1,678,104 | 25 | 3.2 | 22,433 |
| 65-74 | 10,091 | 44.7 | 2.5 | 55,577 | 68 | 1,540,469 | 28 | 3.4 | 22,553 |
| 75-84 | 10,625 | 46.7 | 2.3 | 52,885 | 69 | 1,571,602 | 30 | 3.3 | 22,773 |
| 85 and older | 9,474 | 49.9 | 2.2 | 41,957 | 75 | 1,434,210 | 34 | 4.0 | 19,000 |
| Unknown | 0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Basis of Eligibility^c | | | | | | | | | |
| Aged | 20,618 | 45.9 | 2.1 | 95,882 | 69 | 3,095,019 | 32 | 3.6 | 44,948 |
| Disabled | 27,811 | 45.9 | 2.6 | 158,797 | 71 | 4,288,558 | 27 | 3.3 | 60,644 |
| Adults | 191 | 23.2 | 1.0 | 793 | 25 | 20,222 | 26 | 3.7 | 823 |
| Children | 1 | 16.7 | 0.3 | 2 | 3 | 16 | 8 | 0.1 | 6 |
| Unknown | 6 | 85.7 | 1.1 | 8 | 17 | 120 | 15 | 0.9 | 7 |
| Gender | | | | | | | | | |
| Female | 36,298 | 49.2 | 2.5 | 187,619 | 72 | 5,325,280 | 28 | 3.4 | 73,739 |
| Male | 12,329 | 37.7 | 2.1 | 67,863 | 64 | 2,078,655 | 31 | 3.6 | 32,688 |
| Unknown | 0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0.0 | 1 |
| Race | | | | | | | | | |
| White | 28,624 | 52.4 | 3.0 | 165,676 | 85 | 4,669,789 | 28 | 3.6 | 54,662 |
| African American | 15,845 | 37.9 | 1.6 | 67,869 | 48 | 2,019,702 | 30 | 3.0 | 41,822 |
| Other/unknown | 4,158 | 41.8 | 2.2 | 21,937 | 72 | 714,444 | 33 | 3.8 | 9,944 |
| Use of Nursing Facilities^d | | | | | | | | | |
| Entire year | 10,719 | 62.5 | 3.3 | 55,771 | 112 | 1,911,670 | 34 | 3.9 | 17,137 |
| Part year | 3,937 | 57.2 | 2.8 | 19,060 | 101 | 693,857 | 36 | 4.6 | 6,886 |
| None | 33,971 | 41.2 | 2.2 | 180,651 | 58 | 4,798,408 | 27 | 3.2 | 82,405 |
| Maintenance Assistance Status | | | | | | | | | |
| Cash | 32,120 | 42.7 | 2.3 | 169,887 | 59 | 4,417,817 | 26 | 3.1 | 75,152 |
| Medically needy | 0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Poverty related | 540 | 19.6 | 0.7 | 1,906 | 20 | 55,660 | 29 | 4.1 | 2,759 |
| Other/unknown | 15,967 | 56.0 | 2.9 | 83,689 | 103 | 2,930,458 | 35 | 4.1 | 28,517 |

Table D11

Dual Eligible Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table D.11 includes the beneficiaries represented by Cell G of Table 1. Beneficiaries include all dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.12
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 ALABAMA, 2002

| Beneficiary Characteristics | No. Rx per Bene Mo. | Rx \$ per Bene Mo. | \$ per Rx | Barbiturate \$ per Bene Mo. | Benzodiazapine \$ per Bene Mo. | No. of Bene Mos |
|--|---------------------|--------------------|-----------|-----------------------------|--------------------------------|-----------------|
| All | 0.2 | \$6 | \$29 | \$0 | \$2 | 1,144,370 |
| Age | | | | | | |
| 5 and younger | 0.2 | 16 | 71 | 0 | 0 | 66 |
| 6-14 | 0.1 | 5 | 80 | 0 | 0 | 224 |
| 15-20 | 0.1 | 4 | 45 | 0 | 0 | 2,788 |
| 21-44 | 0.2 | 6 | 30 | 0 | 1 | 210,643 |
| 45-64 | 0.3 | 7 | 25 | 0 | 2 | 242,955 |
| 65-74 | 0.2 | 6 | 28 | 0 | 2 | 248,462 |
| 75-84 | 0.2 | 6 | 30 | 0 | 2 | 246,149 |
| 85 and older | 0.2 | 7 | 34 | 0 | 1 | 193,083 |
| Unknown | 0.0 | 0 | 0 | 0 | 0 | 0 |
| Basis of Eligibility^c | | | | | | |
| Aged | 0.2 | 7 | 32 | 0 | 1 | 468,312 |
| Disabled | 0.2 | 6 | 27 | 0 | 2 | 668,476 |
| Adults | 0.1 | 3 | 26 | 0 | 1 | 7,432 |
| Children | 0.0 | 0 | 8 | 0 | 0 | 66 |
| Unknown | 0.1 | 1 | 15 | 0 | 0 | 84 |
| Gender | | | | | | |
| Female | 0.2 | 7 | 28 | 0 | 2 | 798,018 |
| Male | 0.2 | 6 | 31 | 0 | 1 | 346,340 |
| Unknown | 0.0 | 0 | 0 | 0 | 0 | 12 |
| Race | | | | | | |
| White | 0.3 | 8 | 28 | 0 | 2 | 577,300 |
| African American | 0.1 | 4 | 30 | 0 | 1 | 459,505 |
| Other/unknown | 0.2 | 7 | 33 | 0 | 2 | 107,565 |
| Use of Nursing Facilities^d | | | | | | |
| Entire year | 0.3 | 11 | 34 | 0 | 2 | 170,983 |
| Part year | 0.3 | 10 | 36 | 0 | 2 | 67,252 |
| None | 0.2 | 5 | 27 | 0 | 2 | 906,135 |
| Maintenance Assistance Status | | | | | | |
| Cash | 0.2 | 5 | 26 | 0 | 2 | 837,390 |
| Medically needy | 0.0 | 0 | 0 | 0 | 0 | 0 |
| Poverty related | 0.1 | 2 | 29 | 0 | 1 | 25,148 |
| Other/unknown | 0.3 | 10 | 35 | 0 | 2 | 281,832 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table D.12 includes the beneficiaries represented by Cell G of Table 1. Beneficiaries include all dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002.
 - b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
 - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
 - d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract, OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.13
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 FOR SELECTED DRUG CATEGORIES AMONG DUALS^{a,b,c}
 ALABAMA, 2002

| Drug Category | No. Users | Rx \$ per User | Total Rx \$ | Rx \$ as % of All Part D Excl Rx \$ | Total No. Rx. | \$ per Rx | No. Rx as % of All Part D Excl Rx |
|------------------------------|---------------|----------------|--------------------|-------------------------------------|----------------|-------------|-----------------------------------|
| All | 63,687 | \$116 | \$7,403,935 | 100.0 % | 255,482 | \$29 | 100.0 % |
| Anorexia or weight loss/gain | 4,417 | 333 | 1,472,297 | 19.9 | 8,723 | 169 | 3.4 |
| Fertility drugs | 3,059 | 58 | 178,021 | 2.4 | 3,341 | 53 | 1.3 |
| Drugs for cosmetic purposes | 962 | 966 | 929,366 | 12.6 | 5,433 | 171 | 2.1 |
| Cough and cold medications | 1,039 | 146 | 151,361 | 2.0 | 2,236 | 68 | 0.9 |
| Vitamins and minerals | 605 | 11 | 6,803 | 0.1 | 873 | 8 | 0.3 |
| Non-prescription drugs | 35,722 | 74 | 2,650,382 | 35.8 | 126,747 | 21 | 49.6 |
| Barbiturates | 348 | 19 | 6,579 | 0.1 | 462 | 14 | 0.2 |
| Benzodiazepines | 17,518 | 108 | 1,888,689 | 25.5 | 107,574 | 18 | 42.1 |
| Other Part D Excl Rx Drugs | 17 | 7,085 | 120,437 | 1.6 | 93 | 1,295 | 0.0 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table D.13 includes the beneficiaries represented by Cell G of Table 1. Beneficiaries include all dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2002. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table D11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

SUPPLEMENTAL TABLE 1
 MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES^{a, b}
 ALABAMA, 2002

Total Number of Dual Eligible Beneficiaries 106,428
 Total Pharmacy Reimbursement for Dual Eligible Beneficiaries \$215,405,831
 Mean Pharmacy Reimbursement per Dual Eligible Beneficiary \$2,024

| Annual Pharmacy Reimbursement per Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries | Pharmacy Reimbursement | Percent of Total Pharmacy Reimbursement |
|---|-------------------------|-------------------------------|------------------------|---|
| \$0 | 11,685 | 11.0 % | \$0 | 0.0 % |
| 1-500 | 21,268 | 20.0 | 4,586,286 | 2.1 |
| 501-1,000 | 14,109 | 13.3 | 10,452,485 | 4.9 |
| 1,001-1,500 | 11,227 | 10.5 | 13,950,624 | 6.5 |
| 1,501-2,000 | 9,179 | 8.6 | 15,999,075 | 7.4 |
| 2,001-2,500 | 7,725 | 7.3 | 17,321,476 | 8.0 |
| 2,501-3,000 | 6,179 | 5.8 | 16,960,816 | 7.9 |
| 3,001-3,500 | 5,107 | 4.8 | 16,536,570 | 7.7 |
| 3,501-4,000 | 4,058 | 3.8 | 15,188,372 | 7.1 |
| 4,001-4,500 | 3,108 | 2.9 | 13,169,881 | 6.1 |
| 4,501-5,000 | 2,495 | 2.3 | 11,824,494 | 5.5 |
| 5,001-5,500 | 2,004 | 1.9 | 10,499,238 | 4.9 |
| 5,501-6,000 | 1,610 | 1.5 | 9,232,075 | 4.3 |
| 6,001-6,500 | 1,201 | 1.1 | 7,489,868 | 3.5 |
| 6,501-7,000 | 1,036 | 1.0 | 6,984,004 | 3.2 |
| 7,001-7,500 | 782 | 0.7 | 5,664,375 | 2.6 |
| 7,501-8,000 | 637 | 0.6 | 4,930,575 | 2.3 |
| 8,001-8,500 | 515 | 0.5 | 4,247,905 | 2.0 |
| 8,501-9,000 | 391 | 0.4 | 3,420,647 | 1.6 |
| 9,001-9,500 | 338 | 0.3 | 3,123,646 | 1.5 |
| 9,501-10,000 | 244 | 0.2 | 2,379,207 | 1.1 |
| 10,001+ | 1,530 | 1.4 | 21,444,212 | 10.0 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2002.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

SUPPLEMENTAL TABLE 1A
 MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65^{a, b, c}
 ALABAMA, 2002

Total Number of Disabled Dual Eligible Beneficiaries, Age < 65 41,289
 Total Pharmacy Reimbursement for Disabled Dual Eligible Beneficiaries, Age < 65 \$86,563,773
 Mean Pharmacy Reimbursement per Disabled Dual Eligible Beneficiary, Age < 65 \$2,097

| Annual Pharmacy Reimbursement per Beneficiary | Number of Beneficiaries | Percent of Disabled Dual Beneficiaries, Age < 65 | Pharmacy Reimbursement | Percent of Total Pharmacy Reimbursement |
|---|-------------------------|--|------------------------|---|
| \$0 | | 14.9 % | 0 | 0.0 % |
| 1-500 | 6,164 | 23.7 | 1,910,823 | 2.2 |
| 501-1,000 | 9,766 | 11.9 | 3,599,091 | 4.2 |
| 1,001-1,500 | 4,894 | 8.5 | 4,361,683 | 5.0 |
| 1,501-2,000 | 3,513 | 7.0 | 5,027,049 | 5.8 |
| 2,001-2,500 | 2,890 | 5.6 | 5,189,024 | 6.0 |
| 2,501-3,000 | 2,311 | 4.5 | 5,051,177 | 5.8 |
| 3,001-3,500 | 1,840 | 4.0 | 5,355,628 | 6.2 |
| 3,501-4,000 | 1,651 | 3.1 | 4,831,025 | 5.6 |
| 4,001-4,500 | 1,288 | 2.5 | 4,419,210 | 5.1 |
| 4,501-5,000 | 1,043 | 2.1 | 4,111,646 | 4.7 |
| 5,001-5,500 | 867 | 1.9 | 4,052,755 | 4.7 |
| 5,501-6,000 | 773 | 1.6 | 3,696,880 | 4.3 |
| 6,001-6,500 | 644 | 1.3 | 3,380,280 | 3.9 |
| 6,501-7,000 | 542 | 1.2 | 3,204,284 | 3.7 |
| 7,001-7,500 | 475 | 0.9 | 2,748,652 | 3.2 |
| 7,501-8,000 | 379 | 0.8 | 2,553,549 | 2.9 |
| 8,001-8,500 | 330 | 0.7 | 2,399,515 | 2.8 |
| 8,501-9,000 | 291 | 0.5 | 1,739,148 | 2.0 |
| 9,001-9,500 | 199 | 0.5 | 1,747,195 | 2.0 |
| 9,501-10,000 | 189 | 0.3 | 1,356,708 | 1.6 |
| 10,001+ | 139 | 2.7 | 15,828,451 | 18.3 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2002.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

c. This table is limited to dual eligible beneficiaries who were under age 65 and also indicated as disabled in the MAX files. Therefore, dual eligible beneficiaries under age 65 in "adults" or "children" basis-of-eligibility categories in Table D.2 are excluded because they were not classified as disabled in the MAX files. Disabled dual eligible beneficiaries age 65 and older are included in Supplemental Tables 1B through 1E, depending on their age.

SUPPLEMENTAL TABLE 1B
 MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER^{a, b}
 ALABAMA, 2002

Total Number of Dual Eligible Beneficiaries, Age 65+ 64,326
 Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 65+ \$128,298,509
 Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 65+ \$1,995

| Annual Pharmacy Reimbursement per Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries, Age 65+ | Pharmacy Reimbursement | Percent of Total Pharmacy Reimbursement |
|--|-------------------------|--|------------------------|--|
| \$0 | 5,099 | 7.9% | 0 | 0.0% |
| 1-500 | 11,317 | 17.6 | 2,639,950 | 2.1 |
| 501-1,000 | 9,155 | 14.2 | 6,810,867 | 5.3 |
| 1,001-1,500 | 7,683 | 11.9 | 9,550,076 | 7.4 |
| 1,501-2,000 | 6,263 | 9.7 | 10,927,109 | 8.5 |
| 2,001-2,500 | 5,392 | 8.4 | 12,083,029 | 9.4 |
| 2,501-3,000 | 4,323 | 6.7 | 11,867,048 | 9.2 |
| 3,001-3,500 | 3,449 | 5.4 | 11,157,922 | 8.7 |
| 3,501-4,000 | 2,759 | 4.3 | 10,315,852 | 8.0 |
| 4,001-4,500 | 2,061 | 3.2 | 8,733,589 | 6.8 |
| 4,501-5,000 | 1,621 | 2.5 | 7,679,941 | 6.0 |
| 5,001-5,500 | 1,228 | 1.9 | 6,430,985 | 5.0 |
| 5,501-6,000 | 964 | 1.5 | 5,523,828 | 4.3 |
| 6,001-6,500 | 658 | 1.0 | 4,103,483 | 3.2 |
| 6,501-7,000 | 554 | 0.9 | 3,731,932 | 2.9 |
| 7,001-7,500 | 402 | 0.6 | 2,908,290 | 2.3 |
| 7,501-8,000 | 306 | 0.5 | 2,369,186 | 1.8 |
| 8,001-8,500 | 223 | 0.3 | 1,840,206 | 1.4 |
| 8,501-9,000 | 191 | 0.3 | 1,672,650 | 1.3 |
| 9,001-9,500 | 148 | 0.2 | 1,367,357 | 1.1 |
| 9,501-10,000 | 105 | 0.2 | 1,022,499 | 0.8 |
| 10,001+ | 425 | 0.7 | 5,562,710 | 4.3 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2002.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

SUPPLEMENTAL TABLE 1E
 MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER^{a, b}
 ALABAMA, 2002

Total Number of Dual Eligible Beneficiaries, Age 85+ 19,000
 Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 85+ \$36,038,185
 Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 85+ \$1,897

| Annual Pharmacy Reimbursement per Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries, Age 85+ | Pharmacy Reimbursement | Percent of Total Pharmacy Reimbursement |
|---|-------------------------|--|------------------------|---|
| \$0 | 983 | 5.2 % | 0 | 0.0 % |
| 1-500 | 3,642 | 19.2 | 877,055 | 2.4 |
| 501-1,000 | 3,011 | 15.8 | 2,230,691 | 6.2 |
| 1,001-1,500 | 2,475 | 13.0 | 3,075,419 | 8.5 |
| 1,501-2,000 | 1,941 | 10.2 | 3,389,758 | 9.4 |
| 2,001-2,500 | 1,553 | 8.2 | 3,476,631 | 9.6 |
| 2,501-3,000 | 1,271 | 6.7 | 3,487,827 | 9.7 |
| 3,001-3,500 | 1,002 | 5.3 | 3,235,914 | 9.0 |
| 3,501-4,000 | 833 | 4.4 | 3,110,633 | 8.6 |
| 4,001-4,500 | 577 | 3.0 | 2,446,318 | 6.8 |
| 4,501-5,000 | 439 | 2.3 | 2,076,333 | 5.8 |
| 5,001-5,500 | 352 | 1.9 | 1,840,544 | 5.1 |
| 5,501-6,000 | 254 | 1.3 | 1,454,616 | 4.0 |
| 6,001-6,500 | 155 | 0.8 | 966,427 | 2.7 |
| 6,501-7,000 | 119 | 0.6 | 802,593 | 2.2 |
| 7,001-7,500 | 112 | 0.6 | 809,385 | 2.2 |
| 7,501-8,000 | 76 | 0.4 | 586,658 | 1.6 |
| 8,001-8,500 | 52 | 0.3 | 429,234 | 1.2 |
| 8,501-9,000 | 43 | 0.2 | 376,916 | 1.0 |
| 9,001-9,500 | 23 | 0.1 | 213,033 | 0.6 |
| 9,501-10,000 | 16 | 0.1 | 155,693 | 0.4 |
| 10,001+ | 71 | 0.4 | 996,507 | 2.8 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2002.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

APPENDIX TABLE A.3
 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | No. of Benes | | | | No. of Bene Mos | | | | | | | |
|--|----------------|---------------|---------------|------------|-----------------|----------|------------------|----------------|----------------|--------------|-----------|-----------|
| | All | Aged | Disabled | Adults | Children | Unknown | All | Aged | Disabled | Adults | Children | Unknown |
| All | 108,751 | 45,980 | 61,933 | 825 | 6 | 7 | 1,174,809 | 481,805 | 685,399 | 7,455 | 66 | 84 |
| Age | | | | | | | | | | | | |
| 5 and younger | 6 | 0 | 6 | 0 | 0 | 0 | 66 | 0 | 66 | 0 | 0 | 0 |
| 6-14 | 21 | 0 | 20 | 0 | 1 | 0 | 224 | 0 | 212 | 0 | 12 | 0 |
| 15-20 | 255 | 0 | 250 | 0 | 5 | 0 | 2,798 | 0 | 2,744 | 0 | 54 | 0 |
| 21-44 | 19,677 | 0 | 19,000 | 677 | 0 | 0 | 214,518 | 0 | 208,261 | 6,257 | 0 | 0 |
| 45-64 | 22,909 | 2 | 22,777 | 124 | 0 | 6 | 249,423 | 23 | 248,272 | 1,056 | 0 | 72 |
| 65-74 | 23,234 | 10,298 | 12,919 | 16 | 0 | 1 | 257,295 | 109,483 | 147,723 | 77 | 0 | 12 |
| 75-84 | 23,391 | 18,037 | 5,348 | 6 | 0 | 0 | 254,074 | 193,360 | 60,663 | 51 | 0 | 0 |
| 85 and older | 19,258 | 17,643 | 1,613 | 2 | 0 | 0 | 196,411 | 178,939 | 17,458 | 14 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gender | | | | | | | | | | | | |
| Female | 75,436 | 36,736 | 37,951 | 738 | 4 | 7 | 820,112 | 388,597 | 424,591 | 6,793 | 47 | 84 |
| Male | 33,314 | 9,244 | 23,981 | 87 | 2 | 0 | 354,685 | 93,208 | 260,796 | 662 | 19 | 0 |
| Unknown | 1 | 0 | 1 | 0 | 0 | 0 | 12 | 0 | 12 | 0 | 0 | 0 |
| Race | | | | | | | | | | | | |
| White | 55,206 | 25,616 | 29,190 | 394 | 2 | 4 | 584,803 | 260,156 | 321,030 | 3,551 | 18 | 48 |
| African American | 43,312 | 16,084 | 26,803 | 419 | 3 | 3 | 478,701 | 175,039 | 299,790 | 3,800 | 36 | 36 |
| Other/unknown | 10,233 | 4,280 | 5,940 | 12 | 1 | 0 | 111,305 | 46,610 | 64,579 | 104 | 12 | 0 |
| Use of Nursing Facilities^c | | | | | | | | | | | | |
| Entire year | 17,252 | 14,332 | 2,920 | 0 | 0 | 0 | 172,647 | 140,795 | 31,852 | 0 | 0 | 0 |
| Part year | 6,939 | 5,539 | 1,400 | 0 | 0 | 0 | 68,290 | 53,660 | 14,630 | 0 | 0 | 0 |
| None | 84,560 | 26,109 | 57,613 | 825 | 6 | 7 | 933,872 | 287,350 | 638,917 | 7,455 | 66 | 84 |
| Maintenance Assistance Status | | | | | | | | | | | | |
| Cash | 77,166 | 24,233 | 52,643 | 289 | 1 | 0 | 863,173 | 271,943 | 588,803 | 2,415 | 12 | 0 |
| Medically needy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Poverty related | 2,768 | 1,190 | 1,437 | 134 | 0 | 7 | 25,472 | 11,622 | 12,786 | 980 | 0 | 84 |
| Other/unknown | 28,817 | 20,557 | 7,853 | 402 | 5 | 0 | 286,164 | 198,240 | 83,810 | 4,060 | 54 | 0 |
| Dual Status^d | | | | | | | | | | | | |
| Full dual, all year | 103,177 | 43,087 | 59,276 | 801 | 6 | 7 | 1,118,085 | 451,819 | 658,911 | 7,205 | 66 | 84 |
| Full dual, part year | 5,574 | 2,893 | 2,657 | 24 | 0 | 0 | 56,724 | 29,986 | 26,488 | 250 | 0 | 0 |
| Managed Care Status | | | | | | | | | | | | |
| FFS all year | 105,646 | 44,602 | 60,209 | 822 | 6 | 7 | 1,139,377 | 466,350 | 665,454 | 7,423 | 66 | 84 |
| FFS part year, with Rx claims | 700 | 309 | 390 | 1 | 0 | 0 | 7,856 | 3,344 | 4,502 | 10 | 0 | 0 |
| FFS part year, no Rx claims | 82 | 37 | 45 | 0 | 0 | 0 | 859 | 390 | 469 | 0 | 0 | 0 |
| MC all year, with Rx claims | 2,056 | 907 | 1,147 | 2 | 0 | 0 | 23,796 | 10,371 | 13,403 | 22 | 0 | 0 |
| MC all year, no Rx claims | 267 | 125 | 142 | 0 | 0 | 0 | 2,921 | 1,350 | 1,571 | 0 | 0 | 0 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table A.3 includes the beneficiaries represented by Cell F of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- d. The "Full dual, all year" group contains beneficiaries who had Medicare as well as Medicaid pharmacy benefits during all months of Medicaid enrollment in 2002. The "Full dual, part year" group contains beneficiaries who had such benefits for some, but not all, months of their enrollment. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.4
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a
 DUAL ELIGIBLE BENEFICIARIES, ALABAMA, 2002

| Beneficiary Characteristics | Benes and | | | | | |
|----------------------------------|-------------------------------|-------------------------------|----------------|---------------------------------|--------------|---------------|
| | Bene Mos in Cell F of Table 1 | Included in Cell G of Table 1 | | Excluded from Cell G of Table 1 | | |
| | No. of Benes | No. of Benes | No. of Benes | No. of Benes | No. of Benes | No. of Benes |
| All | 108,751 | 1,174,809 | 106,428 | 1,144,370 | 0 | 30,439 |
| FFS all year | 105,646 | 1,139,377 | 105,646 | 1,139,377 | 0 | 0 |
| FFS part year, with Rx claims | 700 | 7,856 | 700 | 4,500 | 0 | 3,356 |
| FFS part year, with no Rx claims | 82 | 859 | 82 | 493 | 0 | 366 |
| MC all year, with Rx claims | 2,056 | 23,796 | 0 | 0 | 0 | 23,796 |
| MC all year, with no Rx claims | 267 | 2,921 | 0 | 0 | 0 | 2,921 |

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.